Show Of the Month February 2013
Show of the Month February 2 2013
Show of the Month February 9 2013
Show of the Month February 16 2013
Show of the Month February 23 2013
Alcohol in Moderation Can Reduce Asthma Risk, Study Suggests
Cleaning Jobs Linked to Asthma Risk
Modulation of endothelial nitric oxide by plant-derived products.
A New Herbal Combination, Etana, For Enhancing Erectile Function: An Efficacy And Safety Study In Animals.
USUAL BOWEL TOLERANCE DOSES of ASCORBIC ACID
Extracts from Radix Astragali and Radix Rehmanniae promote keratinocyte proliferation by regulating expression of growth factor receptors.
The Self-Assembling Particles That Come from In SPACE
Alcohol in Moderation Can Reduce Asthma Risk, Study Suggests
Sep. 29, 2011 — Drinking alcohol in moderate quantities can reduce the risk of asthma, according to Danish researchers. The study, presented at the European Respiratory Society's Annual Congress in Amsterdam, found that drinking 1-6 units of alcohol a week could reduce the risk of developing the condition. The research examined 19,349 twins between the ages of 12 and 41 yrs of age. All participants completed a questionnaire at the start and end of the study to compare alcohol intake with the risk of developing asthma over 8 yrs. The results showed that the lowest risk of asthma was seen in the group which had a moderate intake of alcohol, as less than 4% of those who drank 1-6 units per week developed asthma. The highest risk of asthma was observed in people who drunk rarely or never, as they were 1.4-times more likely to develop the condition. Heavy drinkers also had an increased risk of asthma development and were 1.2-times more likely to develop asthma. The results also suggested that a preference for beer drinking was associated with an increased risk of asthma when compared with no preference. Previous studies have found a link between excessive intake of alcohol and asthma attacks; however, this is the first study of its kind to show a link between alcohol intake and the onset of asthma for adults over a long period of time.---- Sofie Lieberoth, from the Bispebjerg Hospital in Denmark, said: "Whilst excessive alcohol intake can cause health problems, the findings of our study suggest that a moderate intake of 1-6 units can reduce the risk of developing asthma. By examining all the factors linked with the development of asthma, we can understand more about what causes the condition and how to prevent it."---Story Source---The above story is reprinted from materials provided by European Lung Foundation, via EurekAlert!, a service of AAAS.
Cleaning Jobs Linked to Asthma Risk
Jan. 21, 2013 — A new study has found strong evidence for a link between cleaning jobs and risk of developing asthma. -Researchers at Imperial College London tracked the occurrence of asthma in a group of 9,488 people born in Britain in 1958. Not including those who had asthma as children, nine per cent developed asthma by age 42. Risks in the workplace were responsible for one in six cases of adult onset asthma – even more than the one in nine cases attributed to smoking, according to the analysis.---=There are many occupations that are thought to cause asthma. In this study, 18 occupations were clearly linked with asthma risk, four of which were cleaning jobs and a further three of which were likely to involve exposure to cleaning products.--Farmers, hairdressers, and printing workers were also found to have increased risk, as previous studies have reported. Farmers were approximately four times more likely to develop asthma as an adult than office workers.---=Besides cleaning products, flour, enzymes, metals, and textiles were among materials in the workplace identified in the study as being linked to asthma risk.---The study’s lead author, Dr Rebecca Ghosh of the MRC-HPA Centre for Environment and Health at Imperial College London, said: “This study identified 18 occupations that are clearly linked with asthma risk, but there are others that did not show up in our analysis, mainly because they are relatively uncommon. Occupational asthma is widely under-recognised by employers, employees and healthcare professionals. Raising awareness that this is an almost entirely preventable disease would be a major step in reducing its incidence.”---
The study, published in the journal Thorax, was funded by Asthma UK and the Colt Foundation.---Malayka Rahman, Research Analysis and Communications Officer at Asthma UK, said: "This research has highlighted a new group of people, specifically those working in occupations related to cleaning, such as cleaners or home-based personal care workers, who may have developed adult onset asthma due to exposure to chemicals they work with on a daily basis. We advise anyone who works in the industries highlighted in this study and who have experienced breathing problems to discuss this with their GP, and we urge healthcare professionals to make sure they consider possible occupational causes in adult onset asthma and tailor their advice to people with asthma accordingly."----Around 5.4 million people in the UK have asthma, some of whom suffer as children and some of whom develop the disease in later life.--Story Source---The above story is reprinted from materials provided by Imperial College London, via AlphaGalileo. ---Journal Reference--Rebecca Elisabeth Ghosh, Paul Cullinan, David Fishwick, Jennifer Hoyle, Chris J Warburton, David P Strachan, Barbara K Butland, Debbie Jarvis. Asthma and occupation in the 1958 birth cohort. Thorax, 2013 DOI: 10.1136/thoraxjnl-2012-202151
Modulation of endothelial nitric oxide by plant-derived products.
Nitric Oxide. 2009 Jun 1;--Authors: Schmitt CA, Dirsch VM
Nitric oxide (NO), produced by endothelial nitric oxide synthase (eNOS), is recognised as a central anti-inflammatory and anti-atherogenic principle in the vasculature. Decreased availability of NO in the vasculature promotes the progression of cardiovascular diseases. EPIDEMIOLOGICAL AND CLINICAL STUDIES HAVE DEMONSTRATED THAT A GROWING LIST OF NATURAL PRODUCTS, AS COMPONENTS OF THE DAILY DIET OR PHYTOMEDICAL PREPARATIONS, MAY IMPROVE VASCULAR FUNCTION BY ENHANCING NO BIOAVAILABILITY. In this article we first outline common pathways modulating endothelial NO production or bioavailability to provide a basis for subsequent mechanistic discussions. Then we comprehensively review natural products and plant extracts known to positively influence eNOS activity and/or endothelial function in vitro orin vivo. WE WILL DISCUSS RED WINE, HIGHLIGHTING POLYPHENOLS, OLIGOMERIC PROCYANIDINS (OPC) AND RESVERATROL AS MODULATORS OF ENDOTHELIAL NO PRODUCTION. Other dietary products and their active components known to activate eNOS include COCOA (OPC AND ITS MONOMER ()EPICATECHIN), POMEGRANATES (POLYPHENOLS), BLACK AND GREEN TEA (FLAVANOIDS, ESPECIALLY EPIGALLOCATECHIN GALLATE), OLIVE OIL (OLEIC ACID AND POLYPHENOLS), AND QUERCETIN, ONE OF THE MOST ABUNDANT FLAVONOIDS IN PLANTS. In addition, phytomedical preparations made from ginkgo, hawthorn and ginseng, as well as formulations used in traditional Chinese Medicine, have been shown to affect endothelial NO production. Recurring phytochemical patterns among active fractions and purified compounds are discussed. In summary, there is increasing evidence that several single natural products and plant extracts influence endothelial NO production. Identification of such compounds and characterisation of their cellular actions may increase our knowledge of the regulation of endothelial NO production and could provide valuable clues for the prevention or treatment of cardiovascular diseases.--PMID: 19497380 [PubMed - as supplied by publisher]
A New Herbal Combination, Etana, For Enhancing Erectile Function: An Efficacy And Safety Study In Animals.
Int J Impot Res. 2009 Jun 4; Authors: Qinna N, Taha H, Matalka KZ, Badwan AA
We present herein a new herbal combination called Etana that is composed of five herbal extracts including Panax Quinquelotius (Ginseng), Eurycoma Longifolia (Tongkat Ali), Epimedium Grandiflorum (Horny Goat Weed), Centella Asiatica (Gotu Kola) and Flower Pollen Extracts. Most of the above-mentioned extracts have a long historical and traditional use for erectile dysfunction (ED). On the basis of the mechanism of action of each of the above, a combination is introduced to overcome several physiological or induced factors of ED. This study was conducted to show an enhancement of erectile function in male rats. The animals were observed for 3 h after each administration for penile erection, genital grooming and copulation mounting, and the penile erection index (PEI) was calculated. The maximum response was observed at the concentration of 7.5 mg kg(-1) of Etana. At a 7.5 mg kg(-1) single dose, the percentage of responding rats was 53+/-7 with a PEI of 337+/-72 compared with 17+/-6 with a PEI of 30+/-10 for control animals. This PEI was significantly (P<0.001) higher than each single component and than the sum of any two herbal components of Etana. When compared with sildenafil citrate, Etana Induced More Pronounced PEI Than 0.36 mg kg(-1), but similar to 0.71 mg kg(-1) of sildenafil. Furthermore, full acute and sub-acute toxicity studies showed no toxic effects of Etana. In conclusion, this study describes a new and safe combination of herbal components that enhance erectile function in male rats. Clinical studies are warranted for evaluating Etana's significance in ED.International Journal of Impotence Research advance online publication, 4 June 2009; doi:10.1038/ijir.2009.18.---PMID: 19494825 [PubMed - as supplied by publisher]
TABLE I - USUAL BOWEL TOLERANCE DOSES of ASCORBIC ACID
GRAMS ASCORBIC ACID NUMBER OF DOSES
CONDITION PER 24 HOURS PER 24 HOURS
normal 4 - 15 4 - 6
mild cold 30 - 60 6 - 10
severe cold 60 - 100+ 8 - 15
influenza 100 - 150 8 - 20
ECHO, coxsackievirus 100 - 150 8 - 20
mononucleosis 150 - 200+ 12 - 25
viral pneumonia 100 - 200+ 12 - 25
hay fever, asthma 15 - 50 4 - 8
food allergy 0.5 - 50 4 - 8
burn, injury, surgery 25 - 150+ 6 - 20
anxiety, exercise and
other mild stresses 15 - 25 4 - 6
cancer 15 - 100 4 - 15
ankylosing spondylitis 15 - 100 4 - 15
Reiter's syndrome 15 - 60 4 - 10
acute anterior uveitis 30 - 100 4 - 15
rheumatoid arthritis 15 - 100 4 - 15
bacterial infections 30 - 200+ 10 - 25
infectious hepatitis 30 - 100 6 - 15
candidiasis 15 - 200+ 6 - 25
FIGURE 1. REPRESENTATIVE DOSES TO TREAT ACUTE SYMPTOMS OF
DISEASE IN PATIENTS VERY TOLERANT TO ASCORBIC ACID
Extracts from Radix Astragali and Radix Rehmanniae promote keratinocyte proliferation by regulating expression of growth factor receptors.
Phytother Res. 2012 Oct;26(10):1547-54
Authors: Ren JW, Chan KM, Lai PK, Lau CB, Yu H, Leung PC, Fung KP, Yu WF, Cho CH
Chinese herbal medicine has long been used as a treatment for wounds. However, the underlying cellular and molecular mechanisms remain largely unknown. In this study it was shown that the proliferation of keratinocytes, which is known to play an important role in wound healing as the major cell type in the epidermis, was promoted by three herbal extracts/natural compounds: NF3 (an extract from the mixture of Radix Astragali (RA) and Radix Rehmanniae (RR) in the ratio of 2:1), stachyose (an isolated compound from Radix Rehmanniae) and extract P2-2 (a sub-fraction from the extract of Radix Astragali). The effect of the herbal extracts/natural compounds on the growth of keratinocytes was not influenced by a high glucose level, a condition similar to diabetic patients who usually suffer from diabetic foot ulcers. Real time RT-PCR results showed that the expression of epidermal growth factor (EGF) receptor, but not transforming growth factor-β (TGF-β) receptor, was up-regulated by NF3. Moreover, treatments with the EGF receptor kinase inhibitor AG1478 and the MEK inhibitor U0126 resulted in the diminishment of the effect of the three herbal extracts/natural compounds on keratinocyte proliferation, indicating that EGF receptor might have a significant role in this action. This study has further elucidated the molecular mechanism under which herbal extracts/natural compounds exert their effects on the wound healing process.---PMID: 22359405 [PubMed - indexed for MEDLINE]
The Self-Assembling Particles That Come from InSPACE
NASA astronaut Suni Williams photographing InSPACE-3 vial assembly after particles redistribution operation on the International Space Station. (Credit: NASA)
Jan. 7, 2013 — Shape-shifting malleable, gelatinous forms are orbiting Earth at this very moment -- assembling and disassembling, growing as they are bombarded by magnetic pulses. These forms will take shape as astronauts run experiments involving smart fluids aboard the International Space Station.--While they may change shape, the forms are not things of science fiction. They are the things of fundamental science.---The purpose of the Investigating the Structures of Paramagnetic Aggregates from Colloidal Emulsions-3, or InSPACE-3, study is to gather fundamental data about Magnetorheological, or MR fluids. These fluids are a type of smart fluid that tends to self-assemble into shapes. When they are exposed to a magnetic field, they can quickly transition into a nearly solid-like state. When the magnetic field is removed, they return to a liquid state[U1] .
"Initially the particles in the fluid form long, thin chains," said Eric Furst, InSPACE-3 principal investigator, University of Delaware, Newark, Del. "The magnetic dipoles induced in the particles cause these singular chains to grow parallel to the applied field. Over time the chains parallel to each other interact and bond together. These 'bundles' of chains become more like columns when the magnetic field is toggled on and off. And these columns grow in diameter with time exposed to a pulsed magnetic field."--This self-directed "bundling" was never before observed until it was seen in an earlier space station investigation, InSPACE-2, which ended in 2009. The results of InSPACE-2 were highlighted in a September 2012 article titled "Multi-scale Kinetics of a Field-directed Phase Transition" published in the Proceedings of the National Academy of Sciences.---"Earlier InSPACE investigations looked at MR fluids composed of spherical, or round, particles," said Bob Green, InSPACE-3 project scientist, NASA's Glenn Research Center, Cleveland, Ohio. "InSPACE-3 is focused on oval or ellipsoid-shaped particles. The expectation is that these shapes will pack differently and form column-like structures differently than in previous experiments. The particles in InSPACE-3 are made of a polystyrene material embedded with tiny nano-sized iron oxide particles[U2] ."---Iron oxide is chemically similar to rust. In fact, when the fluid is mixed, it has a brownish rust-type hue. Astronauts, under the direction of the project team, are currently running a series of experiments on this rust-colored mixture and will continue to do so for the next few months.--"We have six vials of which three are primary and three are backups," said Nang Pham, InSPACE-3 project manager at Glenn. "We'll run 12 tests on each of the three vials of different sized ellipsoid-shaped particles for a total of 36 test runs."--A test run could be changing the frequency of the magnetic pulse, altering the magnetic field strength, or using different particle sizes. The first InSPACE-3 test was Oct. 5. Plans are to complete the test runs in early 2013.---For the investigation, astronauts apply a magnetic field of a certain strength, which is pulsed from a low frequency of around 0.66 hertz up to 20 hertz. The pulse is on for a very short time and then is turned off. Scientists are looking for formation of structures that are at a lower energy state. Typically in an MR fluid application, a constant field is applied and the particles form a gel-like structure. They don't pack very well, so the particles have no definite form. They are like a cloud or hot glass that can form into almost any shape.---In a pulsed field, the on-off magnetic field forces the particles to assemble, disassemble, assemble, disassemble and so on. This on-and-off action occurs in millisecond pulses over the approximately two hours of the experiment. In this pulsed field, the particles organize into a more tightly packed structure. Scientists can then measure and plot the column growth over time.---"The idea is to understand the fundamental science around this directed self-assembly in the hopes of better defining new methods of manufacturing materials composed of small colloidal or nanoparticle building blocks," Furst said.--New manufacturing models resulting from InSPACE-2 and -3 studies could be used to improve or develop active mechanical systems such as new brake systems, seat suspensions, stress transducers, robotics, rovers, airplane landing gears and vibration damping systems.---Coupled with the work of InSPACE-2, the InSPACE-3 investigation into fundamental science could advance these systems and improve how we ride, drive and fly. Thanks to these space station investigations, the fluids that come from space may one day further improve your daily commute, whether on the highway or off the road.---Story Source-The above story is reprinted from materials provided by NASA.
Show of the Month February 9 2013
The Drug Regulatory Agency Warnings on Psychiatric drugs and violence
Antidepressant Birth Defect Drug Warnings
Supplements with aloe vera may slash cholesterol levels by over 40%, suggests a new study with lab rats
MORGELLONS FACE & BODY STRIPPER / SCRUBBER SOLUTION & APPLICATION
Eczema in Infants Linked to Gut Bacteria
Caloric Restriction Has a Protective Effect On Chromosomes
Health Canada Approves Bio-K+® as a New and Effective Mean for the Reduction of Clostridium difficile Infections in Hospitals
The Drug Regulatory Agency Warnings on Psychiatric drugs and violence:
United States, November 2005: The FDA’s Safety Information and Adverse Event Reporting Program reported “homicidal ideation“ as an adverse event of Effexor ER (extended release).
Source: “Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) — November 2005,” FDA MedWatch, November 2005.
United States, March 22, 2004: The FDA Public Health Advisory was issued, on antidepressants stating: “Anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia [severe restlessness], hypomania [abnormal excitement, mild mania] and mania [psychosis characterized by exalted feelings, delusions of grandeur and overproduction of ideas], have been reported in adult and pediatric patients being treated with antidepressants.”
Source: “WORSENING DEPRESSION AND SUICIDALITY IN PATIENTS BEING TREATED WITH ANTIDEPRESSANT MEDICATIONS,” FDA Public Health Advisory, 22 Mar. 2004.
United States, October 1995: The U.S. Drug Enforcement Administration (DEA) said Ritalin use could lead to addiction and that “psychotic episodes, violent behavior and bizarre mannerisms had been reported” with its abuse.
Source: “Methylphenidate,” U.S. Drug Enforcement Administration (DEA), October 1995.
United States, June 28, 2005: The FDA announced its intention to make labeling changes for Concerta and other methylphenidate (Ritalin) products (stimulants) to include, “psychiatric events such as visual hallucinations, suicidal ideation, psychotic behavior, as well as aggression or violent behavior.” The FDA announced its intention to also investigate possible cardiac concerns with these drugs.
Source: “Statement on Concerta and Methylphenidate for the June 30 PAC”, Food and Drug Administration (FDA), June 2005.
Canada, February 2006: Health Canada approved a new warning label for Paxil that read, in part: “A small number of patients taking drugs of this type may feel worse instead of better. For example, they may experience unusual feelings of agitation, hostility or anxiety, or have impulsive or disturbing thoughts, such as thoughts of self-harm or harm to others.“ Health Canada required Paxil’s product information to detail a list of “rare” side effects, affecting fewer than one in 1,000 patients. These include delusions, hostility, psychosis, and psychotic depression.
Source: Kate Jaimet, “’I've learned a lesson in the worst way possible’: What drove a loving father to kill his son?,” Ottawa Citizen, 27 Aug. 2006.
Canada, June 03, 2004: Health Canada issued an advisory to the public that stated that stronger warnings have been placed on antidepressants. These warnings indicate that people taking these drugs at any age are at greater risk of behavioral or emotional changes including self-harm or harm to others. The advisory said, “A small number of patients taking drugs of this type may feel worse instead of better…. For example, they may experience unusual feelings of agitation, hostility or anxiety, or have impulsive or disturbing thoughts that could involve self-harm or harm to others.”
Source: Jirina Vlk, “Health Canada advises Canadians of stronger warnings for SSRIs and other newer anti-depressants,” Health Canada, 2004-31, June 3, 2004.
Japan, May 2009: The Japanese Ministry of Health, Labor and Welfare investigated news reports of antidepressant users “who developed increased feelings of hostility or anxiety, and have even committed sudden acts of violence against others.” After its investigation, the Ministry decided to revise the label warnings on newer antidepressants stating, “There are cases where we cannot rule out a causal relationship [of hostility, anxiety, and sudden acts of violence] with the medication.”
Source: “Japan Revises SSRI Warnings–Hostility, Violence,” Medical News Today, May 28, 2009.
European Union, August 19, 2005: The Commission of the European Communities, representing 25 European countries, endorsed and issued the strongest warning yet against child antidepressant use as recommended by Europe’s Committee for Medicinal Products for Human Use (CHMP). Clinical trials had shown that the drugs caused suicidal behavior including suicide attempts and suicidal ideation, aggression, hostility (predominantly aggression, oppositional behavior and anger) and/or related behavior.
Source: Commission of the European Communities Commission Decision concerning the placement on the market, under Article 21 of the Directive 2001/83/EC of the European Parliament and of the Council, Brussels 19-VIII-2005, C (2205) 3256.
Australia, February 2009: The Australian Therapeutic Goods Administration reported that a boxed warning (the strongest warning) was placed onto the ADHD psychostimulant drug methylphenidate (Concerta and Ritalin) for drug dependence. It warns that chronic abuse of methylphenidate can lead to a marked tolerance and psychological dependence with varying degrees of abnormal behavior and frank psychotic episodes can also occur.
Source: “Boxed Warning, Contraindications and strengthened Precautions for Methylphenidate,” Janssen-Cilag, February 2009.
Australia, December 2004: The Australian Therapeutic Goods Administration published an Adverse Drug Reactions Bulletin recommending that any use of SSRI antidepressants in children and adolescents should be carefully monitored for the emergence of suicidal ideation. In a recent study involving Prozac, it said, there was an increase in adverse psychiatric events of suicide, self-harm, aggression and violence.
Source: “Use of antidepressants in children and adolescents,” The Australian Therapeutic Goods Administration (TGA) published an Adverse Drug Reactions Bulletin, Vol 23, No. 6, Dec. 2004, p. 22.
United States, July 01, 2009: The FDA has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban, aka the antidepressant Wellbutrin) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products. These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide.
Source: “Information for Healthcare Professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics),” FDA, July 1, 2009.
United Kingdom, March 2009: Medicines and Healthcare products Regulatory Agency (UK) published in their Drug Safety Update newsletter new information about Atomoxetine (Strattera, a non-stimulant ADHD drug). They warned that Atomoxetine is associated with treatment-emergent psychotic or manic symptoms in children without a history of such disorders.
Source: Medicines and Healthcare products Regulatory Agency, Drug Safety Update newsletter, Vol. 2, March 8, 2009.
Australia, December 2008: The Australian Adverse Drug Reactions Bulletin published an article about the psychostimulant Modafinil. The bulletin advised that this drug has been reported to cause serious adverse skin and psychiatric reactions including anxiety, hallucination, aggression, and mania.
Source: Adverse Drug Reactions Advisory Committee, Australian Adverse Drug Reactions Bulletin, Vol. 27, No. 6, December 2008.
European Union, November 20, 2008: Eli Lilly included in their Strattera label in Europe warnings that Strattera causes “hallucinations, delusional thinking, mania or agitation in children and adolescents without a prior history of psychotic illness or mania…” Strattera is an antidepressant prescribed as a “non stimulant” drug to treat ADHD.
Source: “Official warnings issued: The ADHD drug Strattera CAUSES psychosis, hallucinations, mania and agitation” TransWorldNews, November 20, 2008.
United States, September 2007: The Vice President of Medical Services at the drug company Cephalon sent out a letter to health care professionals informing them of new warnings for the company’s psychostimulant Provigil. “Updated Safety Information: Warnings regarding serious rash, including Stevens Johnson Syndrome [a life-threatening condition affecting the skin] and hypersensitivity reactions, and psychiatric symptoms (including anxiety, mania, hallucinations, and suicidal ideation). 1. Provigil can cause life-threatening skin and other serious hypersensitivity reactions… 2. Provigil is not approved for use in pediatric patients for any indication. 3. Provigil can cause psychiatric symptoms.”
Source: Jeffrey M. Dayno, M.D., “Dear Healthcare Professional,” Cephalon, September 2007.
United States, February 21, 2007: The FDA directed ADHD drug manufacturers to distribute “patient friendly” guides to consumers warning about serious psychiatric and cardiovascular problems, including stroke, heart attack, sudden death and psychotic reactions caused by ADHD drugs. The psychiatric adverse events included hearing voices, becoming suspicious for no reason, or becoming manic, even in patients who did not have previous psychiatric problems.
Source: “FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events,” FDA News, February 21, 2007.
United States, August 21, 2006: The FDA said that ADHD drug manufacturers have to strengthen their warning labels to warn that the drugs can cause suppression of growth, psychosis, bipolar illness, aggression, and ‘serious’ cardiovascular side effects, including misuse possibly leading to sudden death from heart attacks and strokes. Psychostimulant drug companies GlaxoSmithKline and Shire posted a letter to doctors about the revised prescribing information.
Source: “UPDATE 2-US FDA calls for new warnings on ADHD drugs”, Reuters, August 21, 2006.
European Union, April 25, 2005: The European Medicines Agency’s scientific committee, the Committee for Medicinal Products for Human Use, concluded that Prozac-type antidepressants were associated with increased suicide-related behavior and hostility in young people. The London-based watchdog said it recommended the inclusion of strong warnings across the whole of the European Union to doctors and parents about these risks and that the drugs should not be used in children and adolescents in off label situations.
Source: “EU calls for tougher warnings on antidepressants for kids” News-Medical.net April 25, 2005.
United Kingdom, September 21, 2004: The British Healthcare Products Regulatory Authority advised that it had issued guidelines that children should not be given most SSRI antidepressants because of clinical trial data showing an increase rate of harmful outcomes, including hostility.
Source: “Antidepressant aggression concern,” BBC News, 21 Sept. 2004.
European Union, April 22, 2004: The European Agency for the Evaluation of Medicinal Products issued a press release to the press and public. In this press release, they reported that, according to clinical trials, Paroxetine (Paxil in the U.S.) containing medicines could cause suicidal behavior and hostility in children. It recommended that Paroxetine not be used in children and recommended that young adults be observed carefully for signs and symptoms of suicidal behavior or hostility. Paroxetine was shown to have little effectiveness in children according to clinical trials. The committee also recommended strengthened warnings on the withdrawal symptoms of paroxetine, which are common.
Source: “European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products 20-22 April 2004″ EMEA, The European Agency for the Evaluation of Medicinal Products, Press Release April 2004.
Canada, August 22, 2003: Wyeth Pharmaceuticals, the makers of the antidepressant Effexor, issued a warning to U.S. and Canadian doctors that use of this drug could cause hostility, suicidal ideation and self-harm in patients under the age of 18.
Source: Wyeth Pharmaceuticals, “Dear Health Care Professional…” Health Canada, Health Products and Food Branch, August 22, 2003.
United States, May 2007: The FDA’s MedWatch system published a warning on the psychostimulant Desoxyn which is used for ADHD stating that the drug could cause: sudden death with pre-existing structural cardiac abnormalities or other serious heart problems, psychiatric adverse avents including aggression and the emergence of new psychotic or manic symptoms, long-term suppression of growth, seizures, visual disturbance, as well as serious cardiovascular adverse event.
Source: Food and Drug Administration (FDA), “Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)”, MedWatch, May 2007
Antidepressant Birth Defect Drug Warnings:
There have been 15 drug regulatory agency warnings from seven countries (United States, United Kingdom, Ireland, Canada, Australia, New Zealand, and Germany), showing how antidepressants have been tied to birth defects, listed below:
United States, December 14, 2011: The FDA notified healthcare professionals and the public about the use of selective serotonin reuptake inhibitor (SSRI) antidepressants, by women during pregnancy and the potential risk of a rare heart and lung condition known as Persistent Pulmonary Hypertension of the Newborn (PPHN). Source: “Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants: Drug Safety Communication – Use During Pregnancy and Potential Risk of Persistent Pulmonary Hypertension of the Newborn” FDA, December 14, 2011, http://www.fda.gov/drugs/drugsafety/ucm283375.htm
United States, April 01, 2011: The FDA issued label changes to the antidepressant Prozac to warn of the potential risk of cardiovascular defects in infants exposed during first trimester of pregnancy. In addition, the following side effects were added to the “Adverse Reaction” section: balance disorder, bruxism (habitual grinding of teeth), gynecological bleeding, hypotension (low blood pressure), alopecia (hair loss), dysuria (painful urination), micturition (urination) disorder and depersonalization. Source: “Prozac (fluoxetine hydrochloride), Detailed View: Safety Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)” FDA, April 2011, http://www.fda.gov/Safty/MedWatch/SafetyInformation/ucm255402.htm
New Zealand, September 01, 2010: MedSafe (NZ) issued information in their Prescriber Update publication about the use of antidepressants during pregnancy. The Medicines Adverse Reactions Committee (after reviewing studies on two types of antidepressants – SSRIs and SNRIs) concluded that there is a small increased risk of heart birth defects associated with fluoxetine (Prozac), similar to that seen with Paroxetine (Paxil). Also, there is a possibility of this increased risk for all SSRIs or SNRIs antidepressants (not just Paxil and Prozac). In addition to the risk of birth defects, SSRIs and SNRIs antidepressants have been associated with an increase in risk of pre-term birth, persistent pulmonary hypertension (little or no blood flow enters into an infants lungs after birth) and newborn withdrawal symptoms. Source: “The use of antidepressants in pregnancy,” Prescriber Update, MedSafe, Vol. 31, No. 3, Sept. 2010.
United Kingdom, May 01, 2010: The UK’s Medicines and Healthcare products Regulatory Agency issued a warning about the use of SSRIs (selective serotonin reuptake inhibitor) antidepressants in pregnancy, particularly in the later stages, may increase the risk of persistent pulmonary hypertension, where there is a defect in the newborns arteries causing little or no blood flow to enter the lungs after birth. Source: “SSRIs and SNRIs: risk of persistent pulmonary hypertension in the newborn,” Drug Safety Updates, Medicines and Healthcare products Regulatory Agency, Vol. 3, Iss. 10, May 2010, p. 2.
United Kingdom, March 2010: The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) published in their Drug Safety Update a warning that there was an increased risk of heart birth defects with the use of the antidepressant fluoxetine (Prozac) in the first three months of pregnancy, similar to that seen with paroxetine. Source: “Fluoxetine: possible small risk of congenital cardiac defects,” Drug Safety Updates, Medicines and Healthcare products Regulatory Agency, Vol. 3, Iss. 8, March 2010.
Ireland, March 2010: The Irish Medicines Board published in there Drug Safety Newsletter, a report warning about the increased risk of heart birth defects and the use of fluoxetine (Prozac) in the first three months of pregnancy. This was based on the European Medicines Agency analysis of the subject, which included nine studies. They found that the risk of having a baby born with a cardiovascular birth defect following the use of fluoxetine during the first trimester is slightly increased. Source: “Fluoxetine and risk of cardiovascular birth defects,” Drug Safety, Irish Medicines Board, Iss. 36, March 2010.
United States, July 19, 2006: The FDA warned of the risk of a fatal lung condition in newborns whose mothers took newer antidepressants during pregnancy. The agency added it was seeking more information about persistent pulmonary hypertension (a heart and lung disorder) in newborns from the drugs. It asked drug makers to list the potential risk on their drug labels. Source: Susan Heavey, “U.S. FDA warns of new antidepressant risks,” Reuters, July 19, 2006.
Germany, May 08, 2006: The German Drug Regulatory Agency (BfArM) issued risk information on the newer antidepressant Paroxetine (Paxil), that it increased the risk of cardiac malformation in newborns when the mother took Paroxetine during her pregnancy. All German drug manufacturers producing Paroxetine drugs were ordered to implement the warning and safety notes on their drug information leaflets. Source: “Questions and answers on Paroxetine,” Risk information of the BfArM, May 8, 2006.
Canada, March 10, 2006: Health Canada issued an advisory warning for antidepressant use in pregnant women. Research shows newer antidepressants may increase risk of a serious lung disorder in newborns. The warning applies to all newer antidepressants including Wellbutrin, Celexa, Cipralex, Prozac, Luvox, Remeron, Paxil, Zoloft, Effexor, Zyban. Source: “Newer antidepressants linked to serious lung disorder in Newborns” Health Canada, March 10, 2005.
Canada, February 25, 2006: Health Canada issued an advisory to the press regarding newer antidepressants being linked to serious lung disorders in newborns. Health Canada advises that pregnant women taking newer antidepressants should discuss the situation with their doctor because of the potential risk to the baby. Source: “Advisory – Newer antidepressants linked to serious lung disorder in newborns” CNW Group, February 25, 2006.
Canada, December 16, 2005: Health Canada issued Important Safety Information on Paxil, publishing GlaxoSmithKline’s letter to healthcare professionals about a Swedish study that had found heart malformations in newborns of mothers taking Paxil during their first trimester. “Due to the potential for discontinuation symptoms, doctors should inform patients that the drug should not be stopped without first discussing it with their doctor,” the letter further states. Source: “New Safety Information Regarding Paroxetine: Second Large Study Shows an Increased Risk of Cardiac Defects, Over Other Antidepressants, Following First Trimester Exposure to Paroxetine” Health Canada, December 16, 2005.
United States, December 08, 2005: The FDA issued a Public Health Advisory that warned physicians about the potential risk to the fetus if they prescribed Paxil to pregnant women in their first trimester. The drug may cause birth defects, including heart malformations. Source: “FDA Public Health Advisory Paroxetine” Food and Drug Administration (FDA), December 8, 2005.
Canada, September 29, 2005: GlaxoSmithKline, after discussions with Health Canada, issued a letter to healthcare professionals advising of a change to their prescribing information stating that Paxil is associated with an increase of congenital malformations when used by pregnant women. Source: “Important Prescribing Information,” GlaxoSmithKline, September 2005.
United States, September 27, 2005: The FDA and GlaxoSmithKline issued a warning that showed a recent study the drug company conducted on 3,581 pregnant women taking Paxil or other antidepressants during their first trimester of pregnancy. They found an increased risk of major congenital [defect at birth] and cardiovascular [heart] malformations at birth for those mothers taking Paxil. The most common defect was malformations between the heart’s two main pumping chambers. Paxil’s website also said, “Babies born to mothers who have taken antidepressants, including newer ones such as Paxil, in the third trimester of pregnancy have reported complications, including difficulties with breathing, turning blue, seizures, changing body temperature, feeding problems, vomiting, low blood sugar, floppiness, stiffness, shakiness, irritability or constant crying…There have also been reports of premature births in pregnant women exposed to SSRIs [newer antidepressants], including Paxil.” Source: Miranda Hitti, “New Study Links Paxil to Twice as Many Birth Defects as Other Antidepressants” WebMD, September 27, 2005.
Australia, September 07, 2005: The Australian Therapeutics Goods Administration issued an information sheet to health professionals warning that use of newer antidepressants-especially Paxil-in early pregnancy could cause congenital heart abnormalities in newborns. It reported that Danish researchers had determined an association in the first trimester of pregnancy. Source: “General information concerning use of SSRI antidepressants in pregnant women” Australian Government, Department of Health and Aging, September 7, 2005.
There have been 18 studies in eight countries (United States, United Kingdom, Australia, Canada, Netherlands, Finland, Denmark and Sweden), which found a connection between antidepressants and birth defects listed below:
Nordic Countries, January 12, 2012: A study published in the British Medical Journal looked at 1.6 million infants born between 1996-2007. The authors found that mothers who used SSRIs late in pregnancy increased the risk of their child being born with a birth defect effecting breathing, known as persistent pulmonary hypertension. This increased risk was more than two folds. Source: Helle Kieler, Miia Artama, Anders Engeland, Orjan Ericsson, Kari Furu, Mika Gissler, Rikke Beck Nielsen, Mette Norgaard, Olof Stephansson, Unnur Valdimarsdottir, Helga Zoega, Bengt Haglund, “Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries,” British Medical Journal, Vol. 344, Jan 12, 2012.
Finland, July 01, 2011: The journal Obstetrics & Gynecology published a Finnish population-based study of 635,583 births, where 6,976 (1.1%) of the fetuses were exposed to SSRIs (newer antidepressants) during their first trimester. The authors found “that exposure to fluoxetine (Prozac) and Paroxetine (Paxil) in early pregnancy is associated with a small but established risk of specific cardiovascular anomalies [heart defects]…” Source: Heli Malm, MD, PhD, Miia Artama, MSc, PhD, Mika Gissler, MSocSc, PhD, and Annukka Ritvanen, MD, “Selective Serotonin Reuptake Inhibitors and Risk for Major Congenital Anomalies,” Obstetrics & Gynecology, Vol. 118, No. 1, July 2011.
Denmark, June 23, 2010: A study in BioMed Central, Ltd., showed how the prescribing of psychotropic drugs in infants is rapidly increasing. In attempts to curb the use of these drugs, regulatory authorities have issued various warnings about risks associated with use of these products in childhood. This team of researchers analyzed data submitted to a national adverse drug reactions (ADR) database to categorize ADRs reported for psychiatric drugs in the Danish pediatric population. They found that almost 20% of psychotropic ADRs were reported for children from birth up to 2 years of age and one half of ADRs were reported in adolescents. The authors concluded that, “The high number of serious ADRs reported for psychotropic medicines in the pediatric population should be a concern for health care professionals and physicians. Considering the higher number of birth defects being reported greater care has to be given while prescribing these drugs for pregnant women.” Source: Lise Aagaard and Ebba H Hansen, “Adverse drug reactions from psychotropic medicines in the paediatric population: analysis of reports to the Danish Medicines Agency over a decade,” BioMed Central Ltd., vol. 3, no. 176, June 23, 2010.
Australia, May 01, 2010: A study in Australian and New Zealand Journal of Psychiatry looked at whether newborn outcomes, including age at birth, growth at birth and then at 1 month, were altered by exposure to antidepressants during pregnancy. They found that antidepressant exposure during pregnancy resulted in an eightfold increase in chance of being born premature, and with a smaller birth weight. This association was not found with depressed mothers. In addition, at 1 month in age, the difference in weight in the exposed group became significantly greater then those not exposed to antidepressants. Source: Andrew J. Lewis, et al, “Neonatal growth outcomes at birth and one month postpartum following in utero exposure to Antidepressant medication,” Australian and New Zealand Journal of Psychiatry, Vol. 44, No. 5, May 2010.
Canada, April 26, 2010: The American Journal of Obstetrics and Gynecology published a study that researched whether maternal bupropion (an antidepressant) treatment in early pregnancy is associated with birth heart defects in the infant. They found that mother’s of infants with left outflow tract heart defects were more likely to have reported taking bupropion. The authors concluded that there is an association between early pregnancy bupropion use and left outflow tract heart defects. Source: Alwan S, Reefhuis J, Botto LD, et al., “Maternal use of bupropion and risk for congenital heart defects.” American Journal of Obstetrics and Gynecology, Volume 203, Issue 1 , Pages 52.e1-52.e6, July 2010.
Denmark, March 01, 2010: The journal Pediatrics published a study that investigated the possible association between antidepressant exposure (including Paxil) to the fetus during pregnancy and normal milestone developments at 6 and 19 months. Their concluding research found that exposure to antidepressants affected fetal brain development. Source: Lars Henning Pedersen, MD, et al., “Fetal Exposure to Antidepressants and Normal Milestone Development at 6 and 19 Months of Age,” Pediatrics, Vol. 125, No. 3, March 3, 2010.
Sweden, January 05, 2010: Authors of a study published in Psychological Medicine investigated possible adverse effects of the use of antidepressant medication during pregnancy. They reviewed 14,821 women from the Swedish Medical Birth Register. The researchers found that there was an association between antidepressant treatment and many pregnancy complications, notably after tricyclic antidepressant use. An association between use of Paroxetine (Paxil) and birth heart defects and urinary tube defects was also found. The authors concluded that women using antidepressants during pregnancy and their newborns have an increase in health issues. Source: M. Reis, and B. Kallen, “Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data,” The Psychological Medicine, 1-11, [Epub ahead of print], Jan. 5, 2010.
United States, January 01, 2010: A study published in the Current Drug Delivery researched the “under evaluated” impact of antidepressant use during pregnancy on the risk of spontaneous abortion. After reviewing the data collected, they said the information suggests fetal exposure to antidepressants, especially Paroxetine (Paxil) and venlafaxine (Effexor), can lead to spontaneous abortion. Source: Broy, Perrine and Berard, Anick., “Gestational Exposure to Antidepressants and the Risk of Spontaneous Abortion: A Review,” Current Drug Delivery, Vol. 7, No. 1, January 2010.
United States, December 01, 2009: A study in the American Journal of Obstetrics & Gynecology looked at the effects of psychiatric drugs taken during pregnancy on fetal outcomes. It found that Selective serotonin receptor inhibitors (SSRIs – newer antidepressants) were associated with preterm deliveries when women started treatment after the first trimester. The researchers recommend more studies about risks and benefits of psychotropic medication use during pregnancy. Source: Ronit Calderon-Margalit, MD, MPH, et al., “Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy” American Journal of Obstetrics & Gynecology, Vol. 201, Iss. 6, Page 579, December 2009.
United Kingdom, September 23, 2009: A study published in the British Medical Journal reviewed the chances of SSRIs (newer antidepressants) causing birth defects when taken during pregnancy. The authors found a significant increase in risk of septal (the muscle wall that divides the heart chambers) heart defects among children who’s mothers took SSRIs during pregnancy, particularly with sertraline and citalopram. This risk nearly doubled when more then one SSRI was taken. Source: Lars Henning Pedersen, et al, “Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study,” British Medical Journal, Vol. 339, September 23, 2009.
Canada, September 01, 2009: The journal Current Drug Safety published a study that found when pregnant women used Paroxetine (Paxil) during the stage in pregnancy when their baby’s organs are being developed, there was a connection to the increased risk of heart malformations. Source: Simoncelli M, Martin BZ, Brard A, “Antidepressant Use during Pregnancy: A Critical Systematic Review of the Literature,” Current Drug Safety, September 1, 2009.
Netherlands, August 14, 2009: The journal BJOG: An International Journal of Obstetrics & Gynaecology published a study that found children of mothers who used antidepressants during pregnancy showed increased healthcare use during the first year of life, independent of the mother’s healthcare use, and had an increased risk of major cardiac interventions such as cardiovascular surgery or heart catheterization in early childhood. Source: TF Ververs, et al., “Association between Antidepressant drug use during pregnancy and child healthcare utilization,” BJOG: An International Journal of Obstetrics & Gynaecology, August 14, 2009.
United States, October 24, 2007: A study presented at the 54th Annual Meeting of the American Academy of Child & Adolescent Psychiatry by Sheila Marcus, MD, found that babies born to mothers who take antidepressant drugs during pregnancy have high levels of cortisol (primary stress hormone) in cord-blood at birth, and their mothers are more likely to experience delivery complications. Source: Sheila Marcus, M.D., “Antidepressant Medication and Depression Status: Impact on Neonatal Outcomes,” presented at the 54th Annual Meeting of the American Academy of Child & Adolescent Psychiatry, October 24, 2007.
United States, June 28, 2007: A study published in the New England Journal of Medicine found that infants born to women taking commonly prescribed newer antidepressants during the first trimester of their pregnancies have a slightly higher risk of life-threatening birth defects. Source: Carol Louik, Sc.D., et al., “First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects,” New England Journal of Medicine, Vol. 356, No. 26, June 28, 2007.
Canada, December 29, 2006: A new study published in Birth Defects Research Part B: Developmental and Reproductive Toxicology on Paxil, found that Paxil and other antidepressant use in pregnant women increased the possibility that their babies would be born with birth defects. Source: Roman Bystrianyk, “Paroxetine (Paxil or Paxil CR) can more than triple major cardiac birth Defects,” Health Sentinel, December 29, 2006 citing: Birth Defects Research Part B: Developmental and Reproductive Toxicology, December 2006.
Denmark, November 01, 2006: An Epidemiology study found that pregnant women who took newer antidepressants were more likely to have babies with birth defects than mothers who didn’t take these drugs. Source: Wogelius, Pia, Norgaard, Mette, Gislum, Mette, Pedersen, Lars, Munk, Estrid, et al., “Maternal Use of Selective Serotonin Reuptake Inhibitors and Risk of Congenital Malformations,” Epidemiology, Vol. 17, No. 6, November 2006.
Finland, July 15, 2003: A Finnish study published in the Archives of General Psychiatry found that infants whose mothers took newer antidepressants during pregnancy could suffer neurological problems during their first week of life. The symptoms included tremors, restlessness and rigidity. Source: “Newer Antidepressants Can Harm Newborns,” Connecticut Post, July 15, 2003.
United States, May 01, 1993: A study published in the Journal of the American Medical Association found that out of 117 mother who took fluoxetine (Prozac) during the first trimester had a 14.8% risk of miscarriage compared to 7.8% in mothers not exposed to fluoxetine or older antidepressants. There were 19 spontaneous abortions and 13 abnormalities, including heart and small intestine defects in the Prozac group. One baby was born with clubfeet, and a second with a congenital dislocation of the hip. In comparison, there were only 10 spontaneous abortions and 4 anomalies in the non-drug group. Source: Anne Pastuszak, BSc, et al., “Pregnancy Outcome Following First-Trimester Exposure to Fluoxetine (Prozac),” Journal of The American Medical Association, Vol. 269, No. 17, May 5, 1993.
Antidepressant Side Effects Reported to the FDA:
There have been 6,011 birth defects adverse reactions that have been reported to the US FDA’s Adverse Event Reporting System (MedWatch), between 2004 and 2011, these break down to:
3,386 cases of antidepressants causing heart problems
2,190 cases of antidepressants causing general birth defects
218 cases of a antidepressants causing lung and heart defect causing normal blood circulation failure
217 cases of antidepressants causing clubfoot
*********************************************************************************Supplements with aloe vera may slash cholesterol levels by over 40%, suggestsa new study with lab rats
The combination was also associated with similar significant reductions in triacylglycerol levels, and a 12% increase in HDL cholesterol levels, according to findings published in An optimized blend of the probiotic LGG and aloe vera gel could be exploited as a potential biotherapeutic remedy to decrease cholesterol levels and lower the risk of CVD, although the field is open for further studies wrote researchers led by Manoj Kumar, PhD, from India’s National Institute of Nutrition High cholesterol levels, hypercholesterolemia, have a long association with many diseases, particularly cardiovascular disease (CVD), the cause of almost 50 per cent of deaths in Europe and the USA recent report from the American Heart Study The Indian researchers divided lab rats into four groups: The first group acted as the control and was fed a normal diet; the other three groups were fed a hypercholesterolemic diet with supplemental LGG, Aloe vera gel, or a combination of both for 45 days Results showed that LGG consumption alone was associated with a 32% reduction in total cholesterol levels, and this increased to 43% when administered in combination with Aloe vera In addition to the improvements in triacylglycerol and HDL levels, the LGG Aloe vera combination was also associated with reductions in very low-density (VLDL) and low-density lipoprotein (LDL) of 45% and 30%, respectively “There has been a surge of interest in using phytometabolites for nutritional and health applications,” wrote the researchers.“The present study showed that probiotic-fermented milk alone or in combination with AV gel had a positive effect on the lipid profile in experimental animals, although the mechanisms involved warrant further investigations.
Special Note—any combo with aloe or yogurt or kefir ---will have a profound effect on the intestinal and stomach health—aloe will effect-- Aloe vera (consumed orally or applied topically) may inhibit various types of Detrimental Bacteria and Aloe vera (gel applied topically for long periods) may prevent Detrimental Bacteria from penetrating the Skin. references Bacteria inhibited by Aloe vera include: ---Bacillus subtilis -Citrobacter species --Enterobacter cloacae Eschericia coli --Klebsiella pneumoniae --Mycobacterium tuberculosis --Propionibacterium acnes--Pseudomonas aeruginosa --Salmonella species --Serratia marcescens --Staphylococcus aureus---Streptococcus agalactiae --Streptococcus faecalis -Streptococcus pyogenes -- Yogurt may stimulate the growth of Immune Cells to combat the Detrimental Bacteria within the Digestive Tract that cause Diarrhea. --May help to prevent Gastric Ulcers (due to the Lactobacillus acidophilus content of Yogurt inhibiting Helicobacter pylori, the Detrimental Bacteria that is implicated in Gastric Ulcers).- May stimulate the production of Antibodies (due to Beneficial Bacteria in Yogurt). May prevent some forms of Cancer--High consumption of Yogurt may help to prevent Breast Cancer. -- May help to prevent Colon Cancer (due to Beneficial Bacteria in Yogurt detoxifying the Heterocyclic Aromatic Amines (HAAs) that may initiate Colon Cancer).--May inhibit the proliferation of Candida albicans (by recolonizing the Digestive Tract with Beneficial Bacteria). May inhibit the growth of Detrimental Bacteria in the Intestine (due to the presence of Beneficial Bacteria within the Digestive Tract)-May suppress the proliferation of Eschericia coli.- May inhibit Pseudomonas aeruginosa. May increase the resistance of the Digestive System to Salmonella infection. --Yogurt may suppress the proliferation of Staphylococci aureus Bacteria---=Yogurt may stimulate the Immune System. -- Yogurt may lower serum Cholesterol levels by up to 30%-Yogurt may increase HDL Cholesterol levels.—Kefir-will as well provide beneficial bacteria as well as enzymes
MORGELLONS FACE & BODY STRIPPER / SCRUBBER SOLUTION & APPLICATION.
(Please note that this is NOT a cure! It's purely to assist your system to expel SOME of the fibres, thus reducing the load and resulting in some comfort.)
MUST WATCH: http://www.youtube.com/watch?v=RO5lt2O0Fo8 for a complete demonstration.
1. Aloe Vera Gel - 250ml (Aloe Vera penetrates up to 3 layers of skin)
2. Citric Acid - 1 Heaped Teaspoon
3. PURE powdered Aspirin (Salicyclic Acid) - 1/4 to half Teaspoon (Strips toxins off the skin & reduces inflammation on the skin)
4. Powdered Vit C - 15 grams (OR 1 to 3 HEAPED Teaspoons) Tony varies on this, but says it's NOT as issue!
5. Only added LATER ~ AFTER blending the above 4 as recommended below: IODINE ~ DO NOT ADD NOW!
METHOD for mixing:
1: Blend the above first 4 ingredients together until evenly blended. (1 - 2mins depending on what method you choose to use.)
2. Remove from blender & pour into a PLASTIC lidded container / jar. (Not a metal lid)
3. Add 5th ingredient ~ IODINE (clear & not brown IF available) - 20 - 25 drops (Iodine breaks down METAL, so don't put it in your blender or beat with a metal whisk ~ Iodine also helps to rid the system of any radiation poisoning).
1. If you have Colloidal Copper or Silver, you can add a little.
2. You can add about 5 - 8 drops of any Essential Oil (NOT Tea Tree Oil!) to scent your mix. eg. Lemon Grass
METHOD for application:
1. Pour a little at a time into the palm of your hand and lightly rub / blend all over your skin ~ but NOT the genitals where it may sting.
2. After sometime ??? - you will probably or more than likely notice tiny 'fibres' surfacing. THESE ARE STILL TOXIC & dangerous, so it would be best to take a special Morgellons BATH afterwards, to wash these toxic fibres off.
1. Use Betadine SOAP.
2. Add 1/4 Cup if each added to your bath water ~ BICARB OF SODA; TSP (Trisodium phosphate); Epsom Salts OR if available, but not necessary, you can possibly add 1 ounce of "Miracle" Salt in place of Epsom Salts.
3. Add 1 CAP of Betadine solution.
5. Fill the bath as high as possible and sit in it for at least 20 minutes, then use a nice soft body-scrub brush & start brushing!!!
6. Once toweled down (put that towel in the wash away from other laundry items) and RE-APPLY the above SOLUTION / MIXTURE to whichever parts of your face and/or body that will be exposed to the outdoor elements.
OVERALL AVOIDANCE TIPS:
1. Absolutely AVOID any / ALL GMOs (Genetically Modified products)!!!
2. When CHEMTRAILS are obvious in your sky, avoid skin exposure whilst outdoors.
3. If you ever see 'web-like' things outdoors, NEVER ever touch them!!!
4. After applying the Stripper Solution, once it dries on the skin, it leaves a slight sheen BARRIER (protection for further contamination), and when coming into contact with Chemtrail poisons, you MAY sometimes even feel as though you have walked through a spiders web. That's because the solution is reacting with whatever toxins are in the atmosphere.
Eczema in Infants Linked to Gut Bacteria
Jan. 21, 2013 — Children with eczema have a more diverse set of bacteria in their guts than non affected children, finds a new study in BioMed Central's open access journal BMC Microbiology. The types of bacteria present were also more typical of adult gut microbes than for toddlers without eczema[U1] .---Eczema is a chronic inflammation of the epidermis. The gut bacteria of children with or without eczema was examined when they were six and 18 months old. At six months all the infants had the same types of bacteria but by 18 months old the children with eczema had more of a type of bacteria normally associated with adults (Clostridium clusters IV and XIVa) while the healthy children had a greater amount of Bacteroidetes.---MSc Lotta Nylund from University of Turku, Finland, who led the project explained, "The composition of bacteria in a child's gut depends on its environment and the food it eats. You would expect that as a child's diet changes so will the bacteria present. The number of bifidobacteria naturally falls with age and in total we found 21 groups of bacteria which changed in this time period. However it is the early change towards adult-type bacteria which seems to be a risk factor for eczema."---Journal Reference-Lotta Nylund, Reetta Satokari, Janne Nikkilä, Mirjana Rajilic-Stojanovic, Marko Kalliomäki, Erika Isolauri, Seppo Salminen and Willem M de Vos (in press). Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease. BMC Microbiology, 2013 [link]
Special Note On Healthy Bacteria--To mimize this while breast feeding consume a good priobiotic enriched yogurt or dairy or a kefir and while gestating the child consume it orally as well---other studies have validated that the increased levels of yogurt during this time will increase the protection for respiratory ad digestive system
Caloric Restriction Has a Protective Effect On Chromosomes
A sustained lowering of food intake over time results in an increase of telomere length -- the ends of chromosomes -- Jan. 23, 2013 — One of the indicators of a cell's health is the state of its DNA and containers -- the chromosomes -- so when these fuse together or suffer anomalies, they can become the source of illnesses like cancer and/or aging processes.--According to a study carried out by a team led by María Blasco, the director of the Spanish National Cancer Research Centre (CNIO) and head of the Telomeres and Telomerase Group, a sustained lowering of food intake over time results in an increase of telomere length -- the ends of chromosomes -- in adult mice, which has a protective effect on the DNA and genetic material.---These beneficial effects on the youth of the chromosomes translate to a lower incidence of cancer and other age-related illnesses. The journal PLOS ONE is to publish the details of this study in its online edition this week.
A lower incidence of cancer and better health---To carry out the study, researchers used young mice -- just three months old -- and reduced their caloric intake by 40[U2] % before observing them until the end of their life cycle.-"We see that mice that undergo caloric restriction show a lower telomere shortening rate than those fed with a normal diet," says Blasco. "These mice therefore have longer telomeres as adults, as well as lower rates of chromosome anomalies," she adds.---To study the effects of this phenomenon on the health of the mammals, researchers observed the incidence of age-related illnesses like cancer. The mice that had been fed a lower calorie intake showed a reduction in the incidence of cancer. Furthermore, these mice also showed a lower incidence of other age-related illnesses such as osteoporosis, greater glucose uptake or improvements in motor coordination.---When the researchers carried out these same experiments with a variety of mice that produce more telomerase -- a protein that lengthens telomeres and protects chromosomes -- they observed that these mice not only enjoyed better health but also lived up to 20% longer.---"We believe that such a significant increase in longevity is due to the protective effect against cancer produced by caloric restriction -- incidents fall by 40% if we compare them with the mice that produce more telomerase and have a normal diet -- and, added to the presence of longer telomeres, this makes the mice live longer and better," says Blasco.---Despite the effects of caloric restriction depending on the genetic characteristics of each organism, this study opens the way to studying the effect other factors and lifestyle habits, such as smoking or exercise, might have on aging.---Furthermore, it is calculated that there are currently more than 10,000 people in the world on some form of controlled caloric restriction, so the observation of these individuals will be decisive in discovering the effects of this type of diet on humans.---=Story Source-The above story is reprinted from materials provided by Centro Nacional de Investigaciones Oncologicas (CNIO), via EurekAlert!, a service of AAAS. --Journal Reference-Elsa Vera, Bruno Bernardes de Jesus, Miguel Foronda, Juana M. Flores, Maria A. Blasco. Telomerase Reverse Transcriptase Synergizes with Calorie Restriction to Increase Health Span and Extend Mouse Longevity. PLoS ONE, 2013; 8 (1): e53760 DOI: 10.1371/journal.pone.0053760
Health Canada Approves Bio-K+® as a New and Effective Mean for the Reduction of Clostridium difficile Infections in Hospitals
Bio-K+®, A UNIQUE FORMULA, TO PLAY AN IMPORTANT ROLE IN RISK REDUCTION OF C.DIFFICILE IN MEDICAL SETTINGS
MONTREAL, Jan. 16, 2013 /CNW Telbec/ - Today, Bio-K Plus International Inc., a leading Canadian biotechnology company, announced that Health Canada has approved its exclusive and patented Bio-K+® probiotic formula to help reduce the risk of Clostridium difficile (C. difficile) infections in hospitalized patients and those in long-term care facilities. Based on solid clinical evidence published in prestigious medical journals, including the American Journal of Gastroenterology, this approval is confirmation that Bio-K+® is a proven safe and effective product. Despite all preventive measures used, C. difficile still remains a high cause of hospital acquired infections (HAIs) responsible for over 1,000 Canadian deaths yearly unrelated to the cause of hospitalization. Health professionals can benefit from this effective product to protect their patients and help fight C. difficile infection at a very low cost compared to C. difficile treatment. ---"Although the company continues its R&D program, the clinical results published to date, on this unique product, have demonstrated its potential of reducing the risk of this prevalent disease. Health Canada's approval is further support for the product's role in prevention of C. difficile associated diarrhea," said Dr. Donald Low, Microbiologist-in-Chief at Mount Sinai Hospital in Toronto.
Making Our Healthcare System Safer---A Canadian hospital study found that of 136,877 hospital admissions, 1 in 100 patients will contract a C. difficile infection, and of those, 1 in 10 will die regardless of the initial reasons for admission. "Bio-K+® is an innovative product that works to reduce the risk of hospital acquired or antibiotic-associated C. difficile infections. Health Canada's approval of Bio-K+® represents a milestone in further recognizing the importance of such products in the prevention landscape," said Dr. Ian Bookman, Gastroenterologist at St. Joseph's Health Center in Toronto. ---In Quebec, there were 3,934 C. difficile infections resulting in 619 deaths (i.e. 16% of infected patients) between 2010 - 2011. Since 2004, the Pierre-Le-Gardeur Hospital in Montreal, reacting to a major outbreak, has used Bio-K+® on its formulary and also provides the product to all patients treated with antibiotics with no exclusion factors, as a risk reduction measure to control C. difficile. -"Our hospital has almost 9 years of pharmaco-vigilance with more than 40,000 patients using Bio-K+® products with no serious adverse events reported and we have maintained one of the lowest rates of C. difficile in the Province of Quebec," said Dr. Pierre-Jean Maziade, Microbiologist and Head Officer of Infection Preventions at Pierre-Le-Gardeur Hospital, Montreal.
About Bio-K Plus International Inc.
Bio-K Plus International Inc. is a Canadian biotechnology company, committed to medical research and to develop breakthrough innovative products capable of improving human health and quality of life. The company has over 100 employees in Canada and the United States. Bio-K+® is a quality probiotic product that is distinguished by its exclusive and patented formula. It is available in fermented drinks or enteric-coated capsules, dispensed in hospitals, pharmacies, health food stores and supermarkets in North America. The company is also GMP certified by NSF International. This certification confirms the commitment of the company to provide high quality products of international standards. www.biokplus.com ---SOURCE: Bio-K+ International Inc.
For further information:
Dr. Serge Carrière
Managing Director, Scientific Affairs
Bio-K Plus International Inc.
Bio-K Plus International Inc.
Cohn & Wolfe | Montréal
Direct line: 514 845-7064 |cellphone: 514-627-6919
[U1]This would imply strongly a contaminant that the child has gotten exposed to as the adult—a carcinogen—a food contaminant or even a food genetically disorienting the colon
[U2]So if you were to explore this take your full caloric intake –example 2000cal a day take 40% that would keave you 1200—so the idea is to keep using that number daily—would see a increase in metabolism—less pollutant build up of foods and chemicals or genetics on the foods—less wear and tear on pancreas and stomach and liver
Show of the Month February 16 2013
Uncovered, the 'toxic' gene hiding in GM crops: Revelation throws new doubt over safety of food
Chemotherapy can backfire, make cancer worse by triggering tumor growth
Splenda’s Many Secrets-- Gut Flora Destruction--Side Effects
Undiagnosed coeliac disease in patients with emphysema-
Serum cholesterol levels and in-hospital mortality in the elderly
Purpose---Although total cholesterol levels among middle-aged persons correlate with long-term mortality from all causes, this association remains controversial in older persons. We explored whether total cholesterol levels were independently associated with in-hospital mortality among elderly patients.
Methods--We analyzed data from a large collaborative observational study, the Italian Group of Pharmacoepidemiology in the Elderly (GIFA), which collected data on hospitalized patients. A total of 6984 patients aged 65 years or older who had been admitted to 81 participating medical centers during four survey periods (from 1993 to 1998) were enrolled. Patients were divided into four groups based on total cholesterol levels at hospital admission: <160 mg/dL (n = 2115), 160 to 199 mg/dL (n = 2210), 200 to 239 mg/dL (n = 1719), and ≥240 mg/dL (n = 940).
Results--Patients (mean [± SD] age, 78 ± 7 years) were hospitalized for an average of 15 ± 10 days. The mean total cholesterol level was 186 ± 49 mg/dL. A total of 202 patients died during hospitalization. Mortality was inversely related to cholesterol levels (<160 mg/dL: 5.2% [110/2115]; 160–199 mg/dL: 2.2% [49/2210]; 200–239 mg/dL: 1.6% [27/1719]; and ≥240 mg/dL: 1.7% [16/940]; P for linear trend <0.001). After adjustment for potential confounders (demographic characteristics, smoking, alcohol use, indicators of nutritional status, markers of frailty, and comorbid conditions), low cholesterol levels continued to be associated with in-hospital mortality. Compared with patients who had cholesterol levels <160 mg/dL, the odds ratios for in-hospital mortality were 0.49 (95% confidence interval [CI]: 0.34 to 0.70) for participants with cholesterol levels of 160 to 199 mg/dL, 0.41 (95% CI: 0.26 to 0.65) for those with cholesterol levels of 200 to 239 mg/dL, and 0.56 (95% CI: 0.32 to 0.98) for those with cholesterol levels ≥240 mg/dL. These estimates were similar after further adjustment for inflammatory markers and after excluding patients with liver disease.
Conclusion--Among older hospitalized adults, low serum cholesterol levels appear to be an independent predictor of short-term mortality
In addition to HAARP, the United States has operated two other ionosphere research sites in recent years, one in Puerto Rico, near the Arecibo Observatory, and the other (known as HIPAS) in Alaska near Fairbanks. Both of these facilities were built with both active and passive radio instrumentation similar to those at the HAARP facility. Interest in the ionosphere is not limited to the US: a five-country consortium operates the European Incoherent Scatter Radar site (EISCAT), a premier ionosphere research facility located in northern Norway near Tromso. Facilities also are located at Jicamarca, Peru; near Moscow, Nizhny Novgorod (“SURA”) and Apatity, Russia; near Kharkov, Ukraine and in Dushanbe, Tadzhikistan. All of these installations have as their primary purpose the study of the ionosphere, and most employ the capability of stimulating to a varying degree small, localized regions of the ionosphere in order to study methodically, and in a detailed manner what nature produces randomly and regularly on a much larger scale.
More information on the HAARP Fact Sheet – Click Here LINK`http`www.haarp.alaska.edu/haarp/factSheet.html`text-align: -webkit-left; `LINK
Uncovered, the 'toxic' gene hiding in GM crops: Revelation throws new doubt over safety of foods
- EU watchdog reveals approval for GM foods fails to identify poisonous gene
- 54 of the 86 GM plants approved contain the dangerous gene
- Gene found in food for farm animals producing meat, milk and eggs
- Biotech supporters argue there is no evidence that GM foods are harmful
By Sean Poulter, Consumer Affairs Editor
A virus gene that could be poisonous to humans has been missed when GM food crops have been assessed for safety[U1] . GM crops such as corn and soya, which are being grown around the world for both human and farm animal consumption, include the gene. --A new study by the EU's official food watchdog, the European Food Safety Authority(EFSA), has revealed that the international approval process for GM crops failed to identify the gene[U2] . A new study conducted by the EU has shown that standard tests for GM foods may be missing a potentially poisonous gene for humans--As a result, watchdogs have not investigated its impact on human health and the plants themselves when assessing whether they were safe. --The findings are particularly powerful because the work was carried out by independent experts, rather than GM critics.-It was led by Nancy Podevin, who was employed by EFSA, and Patrick du Jardin, of the Plant Biology Unit at the University of Liege in Belgium. They discovered that 54 of the 86 GM plants approved for commercial growing and food in the US, including corn and soya, contain the viral gene, which is known as 'Gene VI'. --In this country, these crops are typically fed to farm animals producing meat, milk and eggs.--Significantly, the EFSA researchers concluded that the presence of segments of Gene VI 'might result in unintended phenotypic changes'. --Such changes include the creation of proteins that are toxic to humans. They could also trigger changes in the plants themselves, making them more vulnerable to pests. -Critics say the revelations make clear that the GM approvals process, which has been in place for 20 years, is fatally flawed. --They argue the only correct response is to recall all of the crops and food products involved. Director of the campaigning group, GM Freeze, Pete Riley, said the discovery of the gene, 'totally undermines claims that GM technology is safe, precise and predictable'. He said: 'This is a clear warning the GM is not sufficiently understood to be considered safe. 'Authorisation for these crops must be suspended immediately, and they should be withdrawn from sale, until a full and extended review of their safety has been carried out[U3] .' Typically, GM crops are modified in the laboratory to give them resistance to being sprayed with powerful weed killers such as Monsanto's Round-up. -This means that, in theory, fields can be doused with the chemical, so wiping out the weeds and allowing the food plants to thrive. ---It was previously assumed that virus genes are not present in plants once they are grown in the field and reach consumers, however it is now clear that this is not the case--The modification process involves inserting genes into the plants using a technique that allows them to piggyback on viruses that are commonly found in the soil and plants. It has been assumed that virus genes are not present in the plant once it is grown in the field and reaches consumers, however it is now clear that this is not the case. --A review of the EFSA research in Independent Science News said the presence of the viral gene appears to have been missed by biotech companies, universities and government regulators.'This situation represents a complete and catastrophic system failure[U4] ,' it said. 'There are clear indications that this viral gene might not be safe for human consumption[U5] . It also may disturb the normal functioning of crops, including their natural pest resistance. 'A reasonable concern is that the protein produced by Gene VI might be a human toxin. This is a question that can only be answered by future experiments[U6] .' -Biotech supporters argue that there is no evidence from countries such as the USA that eating GM food causes any harm[U7] . However, the reality is that no health monitoring has taken place to establish this. The findings will embarrass the government and the food and farming Secretary, Owen Patterson, who has embarked on a pro-GM propaganda exercise designed to win over sceptical consumers. -Mr Patterson recently rejected public concerns as 'humbug' and 'complete nonsense'. Policy director at the Soil Association, Peter Melchett said: 'For years, GM companies have made a deliberate and chilling effort to stop independent scientists from looking at their products 'This is what happens when there is a complete absence of independent scrutiny of their GM crops.' Biotech firms are represented by the Agricultural Biotechnology Council(ABC). -Its chairman, Dr Julian Little, said the EFSA study was one small part of a strict and complex scrutiny process. -He said: 'Over the past 25 years, the European Commission has funded more than 130 research projects involving 500 independent research groups which have found no higher risks to the environment or food chain from GM crops than from conventional plants and organisms.--'Furthermore, nearly three trillion meals containing GM ingredients have been eaten without a single substantiated case of ill-health. The combination of these two facts can give consumers a huge amount of confidence in the safety of GM crops[U8] .' GM critics and EFSA are at odds over the implications of the research paper, which was written by the deputy chairman of the organisation’s advisory panel on the issue and a former senior member of staff.---EFSA insists that the research highlighting the presence of Gene VI does not represent a new discovery of a viral gene and does not indicate a safety concern about GM crops already approved.[U9] It said the viral gene ‘cannot infect animals or humans and therefore presents no threat to human or animal health’. This is challenged by GM critics who say there is no research evidence to justify this statement.
North Korean parents 'eating their own children' after being driven mad by hunger in famine-hit pariah state
- Undercover reporters found a 'shocking' number of cannibalism incidents
- Up to 10,000 people feared dead after 'hidden famine' in farming provinces
- Drought and confiscated food contribute to desperate shortage, reports say
- Reports of men digging up corpses for food and murdering children
By Becky Evans
A starving man in North Korea has been executed after murdering his two children for food, reports from inside the secretive state claim. A 'hidden famine' in the farming provinces of North and South Hwanghae is believed to have killed up to 10,000 people and there are fears that incidents of cannibalism have risen[U10] .
The grim story is just one to emerge as residents battle starvation after a drought hit farms and shortages were compounded by party officials confiscating food.--North Korean leader Kim Jong Un has spent vast sums of money on two rocket launches despite reports of desperate food shortages in the country and concerns that 10,000 people have died in a famine[U11] Undercover reporters from Asia Press told the Sunday Times that one man dug up his grandchild's corpse and ate it. Another, boiled his own child for food. Despite reports of the widespread famine, Kim Jong Un, 30, has spent vast sums of money on two rocket launches in recent months. There are fears he is planning a nuclear test in protest at a UN Security Council punishment for the recent rocket launches and to counter what it sees as US hostility. One informant was quoted as saying: 'In my village in May a man who killed his own two children and tried to eat them was executed by a firing squad.'Farming communities, such as these pictured outside the capital Pyongyang last year, have been desperately hit by drought which has led to reports of people turning to cannibalism in a bid to ward off starvation One official said the fields are in such a bad state from drought that he had to avert his eyes [U12] The informant said the father killed his eldest daughter while his wife was away on business and then killed his son because he had witnessed the murder. When his wife returned the man told her they had 'meat' but she became suspicious and contacted officials who discovered part of the children's bodies. Jiro Ishimaru, from Asia Press, which compiled a 12 page report, said: 'Particularly shocking were the numerous testimonies that hit us about cannibalism.' Undercover reporters said food was confiscated from the two provinces and given to the residents of the capital Pyongyang. A drought then left food supplies desperately short[U13] . -Cannibalism has also been reported in the vast network of prison camps inside North Korea, such as Camp 22, pictured, where 50,000 are believed to be imprisoned
The Sunday Times also quoted an official of the ruling Korean Worker's party as saying: 'In a village in Chongdan county, a man who went mad with hunger boiled his own child, ate his flesh and was arrested. United Nations officials visited the area during a state-sponsored trip but local reporters said it is unlikely they were shown the famine-hit areas.--It has not the first time that reports of cannibalism have come out of the country. ---In May last year, the South Korean state-run Korean Institute for National Unification said that one man was executed after eating part of a colleague and then trying to sell the remains as mutton. ---One man killed and ate a girl and a third report of cannibalism was recorded from 2011. --Another man was executed in May after murdering 11 people and selling the bodies as pork. There were also reports of cannibalism in the country's network of prison camps. North Korea was hit by a terrible famine in the 1990s - known as the Arduous March - which killed between 240,000 and 3.5million people.
Chemotherapy can backfire, make cancer worse by triggering tumor growth
Scientists found that healthy cells damaged by chemotherapy secreted more of a protein called WNT16B, which boosts cancer cell survival. 'The increase in WNT16B was completely unexpected," --
Long considered the most effective cancer-fighting treatment, chemotherapy may actually make cancer worse, according to a shocking new study. The extremely aggressive therapy, which kills both cancerous and healthy cells indiscriminately, can cause healthy cells to secrete a protein that sustains tumor growth and resistance to further treatment[U14] . Researchers in the United States made the "completely unexpected" finding while seeking to explain why cancer cells are so resilient inside the human body when they are easy to kill in the lab. They tested the effects of a type of chemotherapy on tissue collected from men with prostate cancer, and found "evidence of DNA damage" in healthy cells after treatment, the scientists wrote in Nature Medicine.--Chemotherapy works by inhibiting reproduction of fast-dividing cells such as those found in tumors. The scientists found that healthy cells damaged by chemotherapy secreted more of a protein called WNT16B which boosts cancer cell survival. "The increase in WNT16B was completely unexpected," study co-author Peter Nelson of the Fred Hutchinson Cancer Research Center in Seattle told AFP. The protein was taken up by tumor cells neighboring the damaged cells. "WNT16B, when secreted, would interact with nearby tumor cells and cause them to grow, invade, and importantly, resist subsequent therapy," said Nelson. In cancer treatment, tumors often respond well initially, followed by rapid re-growth and then resistance to further chemotherapy. Rates of tumor cell reproduction have been shown to accelerate between treatments. -"Our results indicate that damage responses in benign cells... may directly contribute to enhanced tumor growth kinetics," wrote the team. -The researchers said they confirmed their findings with breast and ovarian cancer tumors.
CANCER TREATMENT OVERVIEW
The result paves the way for research into new, improved treatment, said Nelson."For example, an antibody to WNT16B, given with chemotherapy, may improve responses (kill more tumor cells)," he said in an email exchange. "Alternatively, it may be possible to use smaller, less toxic doses of therapy."
Read more: http://www.nydailynews.com/life-style/health/shock-study-chemotherapy-backfire-cancer-worse-triggering-tumor-growth-article-1.1129897#ixzz2JNCoqn69
Splenda’s Many Secrets-- Gut Flora Destruction--Side Effects
It’s becoming increasingly clear that aspartame is bad news. But what about the other artificial sweetener, sucralose (Splenda)? Is Splenda safe?
Known commercially as Splenda, sucralose is a synthetic product—a chlorinated sugar molecule—of McNeil Nutritionals, LLC, a subsidiary of Johnson & Johnson. Splenda continues to be avidly used by consumers watching their weight and blood sugar. The Calorie Control Council is only too happy to tear apart arguments that Splenda may not be as safe as purported, including studies—even by the prestigious Duke University—and assertions by alternative medicine practitioners like Dr. Mercola, who compared sucralose to DDT.
Splenda and DDT
As The Examiner states, “most pesticides are chlorocarbons and…the bonds holding carbon and chlorine atoms together in sucralose are more characteristic of a chlorocarbon than a salt.”---The Calorie Control Council (CCC) claims, rightfully, that DDT is virtually insoluble in water and soluble in fats, such as those found in the body. “The small amount of sucralose that is absorbed is rapidly eliminated in urine.” Splenda’s makers have admitted that, on average, 15 percent of sucralose is absorbed. (Remember that that’s an average, meaning some people may absorb significantly more, others significantly less.)---Because sucralose is not a naturally occurring product, however, it might be safe to say that the body, unable to metabolize it, absorbs it via the digestive system and ultimately stores it in the body. (Perhaps a scientist can peaceably weigh in on this.)
Sucralose and the Gut--Its absorption by the digestive system may explain why researchers at Duke University in 2008 found that Splenda negatively alters gut microflora in rats and may limit the bioavailability of drugs and nutrients (The study can be found here as published in the Journal of Toxicology and Environmental Health.) A myriad other studies showing Splenda’s adverse effects—ranging from bowel disturbances, kidney mineralization, and tumor growth—can be reviewed here.--In one human (albeit small) study, nutritionist Tamara Duker Freuman found that “because [Splenda’s] sweet taste is not accompanied by the calories (energy) our brain expects it to be, the complex systems our bodies have to regulate energy balance may be thrown off kilter. The result is that of a diet high in artificial sweeteners may possibly, over time, cause people to seek out more calories from other sources in order to satisfy cravings that sweet—but calorically empty—foods create.”
Human Bias Affecting Studies
Although the CCC accuses studies like Duke’s as having flaws (specifically, “lack of proper control groups”), one may say the same of the studies used in defense of Splenda. One cited often was published in the November 2010 issue of Food and Chemical Toxicology, in which sucralose was found to have no genotoxicity.
It’s worth noting, however, that the makers of Splenda co-authored the study. Keep in mind, too, that Johnson & Johnson (affiliated with Splenda) was recently hit with a $1 billion fine for marketing Risperdal for unapproved uses and regularly puts toxins like formaldehyde, parabens, and phthalates in many of its products. It was only in 2011 that they promised to take known and possible carcinogens out of its infant care products, and it will take them until 2015 (allegedly) to do the same for adult toiletries.
Here is some information regarding the 110 studies proving Splenda’s safety:
- The 110 “animal and human studies” consisted of 2 studies involving humans, with a total of 36 people involved.
- The longest human study lasted 4 days, and focused on Splenda’s impact on tooth decay.
- Some of the remainder “safety studies” showed Splenda to cause decreased red blood cells, male infertility, brain lesions (at high doses), spontaneous abortions in a rabbit population.
Consumer-Reported Side Effects
Consumers of Splenda have themselves come forward with complaints (which can admittedly have mitigating factors), including:
- Gastrointestinal problems
- Blurred vision
- Allergic response
- Blood sugar increases
- Weight gain
Splenda is comprised of the high-potency artificial sweetener sucralose (1.1%) and the fillers maltodextrin and glucose. Splenda was administered by oral gavage at 100, 300, 500, or 1000 mg/kg to male Sprague-Dawley rats for 12-wk, during which fecal samples were collected weekly for bacterial analysis and measurement of fecal pH. After 12-wk, half of the animals from each treatment group were sacrificed to determine the intestinal expression of the membrane efflux transporter P-glycoprotein (P-gp) and the cytochrome P-450 (CYP) metabolism system by Western blot. The remaining animals were allowed to recover for an additional 12-wk, and further assessments of fecal microflora, fecal pH, and expression of P-gp and CYP were determined. At the end of the 12-wk treatment period, the numbers of total anaerobes, bifidobacteria, lactobacilli, Bacteroides, clostridia, and total aerobic bacteria were significantly decreased; however, there was no significant treatment effect on enterobacteria. Splenda also increased fecal pH and enhanced the expression of P-gp by 2.43-fold, CYP3A4 by 2.51-fold, and CYP2D1 by 3.49-fold. Following the 12-wk recovery period, only the total anaerobes and bifidobacteria remained significantly depressed, whereas pH values, P-gp, and CYP3A4 and CYP2D1 remained elevated. These changes occurred at Splenda dosages that contained sucralose at 1.1–11 mg/kg (the US FDA Acceptable Daily Intake for sucralose is 5 mg/kg). Evidence indicates that a 12-wk administration of Splenda exerted numerous adverse effects, including (1) reduction in beneficial fecal microflora, (2) increased fecal pH, and (3) enhanced expression levels of P-gp, CYP3A4, and CYP2D1, which are known to limit the bioavailability of orally administered drugs.
Undiagnosed coeliac disease in patients with emphysema-
- M. De Menthon*, D.J. Dusser#, L. Guillevin* and P.R. Burgel#
+ Author Affiliations
- *Depts of Internal Medicine,
- #Respiratory Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France
- P.R. Burgel, Service de Pneumologie, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, 27 rue du Faubourg St Jacques, 75679 Paris, Cedex 14, France. E-mail: email@example.com
To the Editors:
Chronic obstructive pulmonary disease (COPD) is characterised by progressive and poorly reversible airflow obstruction due to small airway disease and emphysema. Cigarette smoking is the major cause of COPD, but the disease also occurs in nonsmokers. In nonsmokers, environmental factors (e.g. second-hand smoking and inhalation of toxic gas), genetic factors (e.g. the rare α1-antitrypsin deficiency) and infectious factors (e.g. HIV infection) have been implicated in the pathogenesis of the disease. We report on two cases of COPD with emphysema in nonsmokers with long-standing undiagnosed coeliac disease.
A 71-yr-old female was referred to our hospital (Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France) for dyspnoea and cough, which had evolved over 5 yrs. She had suffered from alternating diarrhoea and constipation for many years, ascribed to functional bowel disease. She had never been exposed to inhaled toxics and had never smoked. Examination revealed a body mass index (BMI) of 18 kg·m−2 and a chest computed tomography (CT) image revealed pulmonary distension and emphysema (fig. 1). Spirometry revealed severe airflow limitation (table 1). Serum α1-antitrypsin was normal. Treatment with long-acting bronchodilators was initiated. After 7 yrs of follow-up, the patient complained of progressive weight loss (BMI 15 kg·m−2) and increased diarrhoea. Vitamin D deficiency was found, suggesting malabsorption. Anti-endomysium, anti-gliadin and anti-transglutaminase antibodies were detected. Gastroscopy revealed a macroscopic aspect of pavimental mucosa and duodenal biopsies showed subtotal villous atrophy with increased numbers of intraepithelial lymphocytes, confirming coeliac disease. Diarrhoea and weight loss improved markedly on a gluten-free diet, but no significant changes in lung function were observed.
View larger version:
a) High-resolution computed tomography images obtained in patient 2 reveals focal areas of low attenuation (arrowheads) within a homogeneous background of lung parenchyma, characterising centrilobular emphysema. b) Bullous emphysema in the same patient.
Table 1– Characteristics of patients
A 59-yr-old female was referred to our hospital (Hôpital Cochin, Assistance Publique-Hôpitaux de Paris) after two episodes of acute bronchitis and weight loss of 5 kg. She had never smoked and had never been exposed to inhaled toxics. She also complained of asthenia, chronic pain of the wrists and fingers, and chronic itching for several years. She signalled that she had always had soft saddles. Examination showed mild malnutrition (BMI 18 kg·m−2). Laboratory tests showed chronic microcytic anaemia and severe iron deficiency. A chest CT image showed centrilobular and bullous emphysema, which predominated in lower lobes (fig. 1). Spirometry showed mild airflow limitation and plethysmography revealed pulmonary hyperinflation. Serum α1-antitrypsin was normal. The patient declined bronchoscopy and no bronchoalveolar lavage was performed. Gastroscopy was performed to explore iron deficiency and showed a typical pavimental aspect of duodenal mucosa. Biopsies revealed total villous atrophy with lymphocytic infiltrate of the mucosa. Antibodies against gliadin, endomysium and transglutaminase were all positive. Further exploration showed marked vitamin D deficiency and severe osteoporosis. Coeliac disease was treated with a gluten-free diet, which resulted in a rapid improvement in itching, joint pain and diarrhoea. No significant changes in pulmonary abnormalities occurred.
Coeliac disease was originally considered a rare malabsorption syndrome of childhood, but is now recognised as a common condition that may be diagnosed at any age. Coeliac disease may affect many organ systems including the neurological system, skin and liver 1. Previous reports have suggested links between coeliac disease and several pulmonary manifestations, including diffuse pulmonary nodules, interstitial fibrosis, lymphocytic bronchoalveolitis and pulmonary haemosiderosis 2. ---An association between emphysema and coeliac disease has been previously suggested 3–5. In a study of a case of malabsorption, intestinal mucosal atrophy and ulceration, cirrhosis, and emphysema, the authors suggested that emphysema was unrelated to coeliac disease because the patient was a heavy smoker 3. In another report, coeliac disease was associated with emphysema, which was ascribed to α1-antitrypsin deficiency 5. In a pathological study of lung specimens obtained in 14 patients (10 current or ex-smokers) with coeliac disease complaining of respiratory symptoms (e.g. dyspnoea and/or cough), Edwards et al. 4 described airflow obstruction in seven patients and peribronchiolar fibrosis in 12 patients. However, because lung function was normal in the four nonsmokers and because most bronchiolar abnormalities were found in current or ex-smokers, the authors suggested that these findings were unrelated to coeliac disease 4. ---Our cases differ from previous reports in that both patients were lifelong nonsmokers and had no α1-antitrypsin deficiency. Although we cannot rule out that the observed associations between coeliac disease and emphysema occurred by chance, our report is consistent with the findings of Tarlo et al. 6 who reported mild airflow obstruction in 18 subjects with biopsy-proven coeliac disease compared with 18 control subjects matched for age, sex and smoking.
Coeliac disease is a unique autoimmune disorder because the environmental precipitant (gluten) is known 1. Recently, evidence has emerged that auto-immunity may be involved in the pathogenesis of alveolar destruction characteristic of emphysema 7. Because autoimmune diseases are often associated, it is possible that both diseases coexist and/or that auto-antibodies share antigen specificity. Another possible explanation is related to long-standing malnutrition. Severe malnutrition caused by starvation during World War II or by anorexia nervosa has been associated with the development of emphysema 8. Furthermore, vitamin D deficiency, which was present in our patients, has been linked with abnormal lung function 9. We suggest that long-standing malabsorption occurring in patients with coeliac disease may induce lung inflammation and emphysema. In support of the latter hypothesis, Brightling et al. 2 reported CD4+ lymphocytic bronchoalveolitis in a 68-yr-old female with a 1-yr history of dry cough, which improved markedly after several months on a gluten-free diet. We could not demonstrate such findings in our patients because patient 1 had severe bronchial obstruction and patient 2 declined bronchoscopy.
In summary, we suggest that coeliac disease diagnosis should be considered in patients with emphysema, especially when classical risk factors for emphysema (e.g. smoking) are absent. Further research is also warranted to examine the prevalence of emphysema in patients with coeliac disease. If confirmed, the association between emphysema and coeliac disease may provide new insights into the pathogenesis of emphysema and coeliac disease.
- Green PH,
- Cellier C
. Celiac disease. N Engl J Med 2007; 357: 1731–1743.
CrossRefMedlineOrder article via InfotrieveWeb of Science
- Brightling CE,
- Symon FA,
- Birring SS,
- et al
. A case of cough, lymphocytic bronchoalveolitis and coeliac disease with improvement following a gluten free diet. Thorax 2002; 57: 91–92.
Abstract/FREE Full Text
A case of malabsorption, intestinal mucosal atrophy and ulceration, cirrhosis, and emphysema. BMJ 1970; 3: 207–212.
FREE Full Text
- Edwards C,
- Williams A,
- Asquith P
. Bronchopulmonary disease in coeliac patients. J Clin Pathol 1985; 38: 361–367.
Abstract/FREE Full Text
- Greenwald AJ,
- Johnson DS,
- Oskvig RM,
- et al
. α-1-Antitrypsin deficiency, emphysema, cirrhosis, and intestinal mucosal atrophy. JAMA 1975; 231: 273–276.
Abstract/FREE Full Text
- Tarlo SM,
- Broder I,
- Prokipchuk EJ,
- et al
. Association between celiac disease and lung disease. Chest 1981; 80: 715–718.
Abstract/FREE Full Text
- Lee SH,
- Goswami S,
- Grudo A,
- et al
. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007; 13: 567–569.
CrossRefMedlineOrder article via InfotrieveWeb of Science
- Coxson HO,
- Chan IH,
- Mayo JR,
- et al
. Early emphysema in patients with anorexia nervosa. Am J Respir Crit Care Med 2004; 170: 748–752.
Abstract/FREE Full Text
- Black PN,
- Scragg R
. Relationship between serum 25-hydroxyvitamin D and pulmonary function in the third national health and nutrition examination survey. Chest 2005; 128: 3792–3798.
Abstract/FREE Full Text
Hydrogen Sulfide- The Next Anti-Aging Agent
Jan. 29, 2013 — Hydrogen sulfide* (H2S) may play a wide-ranging role in staving off aging, according to a paper published online ahead of print in the journal Molecular and Cellular Biology. In this review article, a team from China explores the compound's plethora of potential anti-aging pathways. Hydrogen sulfide (H2S) is the third endogenous signaling gasotransmitter, following nitric oxide and carbon monoxide. It is physiologically generated by cystathionine-γ-lyase, cystathionine-β-synthase, and 3-mercaptopyruvate sulfurtransferase. H2S has been gaining increasing attention as an important endogenous signaling molecule because of its significant effects on the cardiovascular and nervous systems. substantial evidence shows that H2S is involved in aging by inhibiting free-radical reactions, activating SIRT1, and probably interacting with the age-related gene Klotho. Moreover, H2S has been shown to have therapeutic potential in age-associated diseases. This article provides an overview of the physiological functions and effects of H2S in aging and age-associated diseases, and proposes the potential health and therapeutic benefits of H2S.
"H2S has been gaining increasing attention as an important endogenous signaling molecule because of its significant effects on the cardiovascular and nervous systems," the team writes. The evidence is mounting, they note, that hydrogen sulfide slows aging by inhibiting free-radical reactions, by activating SIRT1, an enzyme believed to be a regulator of lifespan, and probably through its interactions with a gene, klotho, which appears to have its own market basket of anti-aging activity.----Hydrogen sulfide is produced within the human body, and has a variety of important physiological effects. For example, it relaxes the vascular endothelium and smooth muscle cells, which is important to maintaining clean arteries as one ages, says first author Zhi-Sheng Jiang, of the University of South China, Hunan. It functions as an antioxidant. And it inhibits expression of pro-inflammatory factors, all of which "imply an important role in aging and age-associated diseases," according to the paper. For example, mice lacking CSE, the gene for an enzyme involved in producing H2S, manifest extensive, premature arteriosclerosis, an inevitable consequence of aging, says Jiang.---The gene, klotho, which appears to be upregulated by hydrogen sulfide, is thought to extend lifespan via a number of different pathways, some of which promote production of endogenous antioxidants, according to the report. Produced in the kidneys, it has direct angiotensin-converting enzyme (ACE) inhibiting activity; that is, it's an ACE inhibitor, just like certain drugs that mitigate high blood pressure. Not surprisingly, plasma H2S declines with age, and is lower in spontaneously hypertensive rats than in those with normal blood pressure. More generally, a lack of H2S is implicated in cardiovascular disease.---A decline in H2S is also thought to undermine neurological health. Endogenous H2S has been found wanting in an animal model of Parkinson's disease, and is found to be depressed in the brains of patients with Alzheimer's disease. There are even suggestions, mostly in animal models, but also in human studies, that H2S may be protective against cancer, according to the report.---"Data available so far strongly suggest that H2S may become the next potent agent for preventing and ameliorating the symptoms of aging and age-associated diseases," concludes Jiang. In the future, he says, people may take H2S via food, or as an anti-aging supplement.----* Hydrogen sulfide (British English: hydrogen sulphide) is the chemical compound with the formula H2S. It is a colorless, very poisonous, flammable gas that gives off the odor of rotten eggs.--Journal Reference-Y. Zhang, Z.-H. Tang, Z. Ren, S.-L. Qu, M.-H. Liu, L.-S. Liu, Z.-S. Jiang. Hydrogen Sulfide: Next Potent Preventive and Therapeutic Agent in Aging and Age-associated Diseases. Molecular and Cellular Biology, 2013; DOI: 10.1128/MCB.01215-12
Function in the body
Hydrogen sulfide is produced in small amounts by some cells of the mammalian body and has a number of biological signaling functions. (Only two other such gases are currently known: nitric oxide (NO) and carbon monoxide (CO).)
The gas is produced from cysteine by the enzymes cystathionine beta-synthase and cystathionine gamma-lyase. It acts as a relaxant of smooth muscle and as a vasodilator and is also active in the brain, where it increases the response of the NMDA receptor and facilitates long term potentiation, which is involved in the formation of memory.
Dairy Products-Most Dairy Products contain Cysteine.--Eggs--Yolks Meats-Most Meats contain Cysteine.—Nuts-Most Nuts contain Cysteine. –Seeds-Most Seeds contain Cysteine.—Vegetables-Garlic & Onions---Broccoli----Brussels Sprouts
Alliin (also known as S-allyl-L-Cysteine Sulfoxide or S-allyl-Cysteine) is a Cysteine derivative present in Garlic.
Cysteine Hydrochloride (Cysteine HCl) is a form of supplemental Cysteine that consists of 77% L-Cysteine bound to 23% Hydrochloric Acid (HCl).
L-Cysteine is the natural endogenous state of Cysteine (i.e. NOT D-Cysteine).
N-Acetyl-Cysteine (NAC) is an endogenous derivative of Cysteine that is regarded by some researchers as the optimal form of supplemental Cysteine. NAC is more water-soluble than regular Cysteine.
S-allylmercaptocysteine is a Cysteine derivative present in Garlic.
S-methyl Cysteine is a Cysteine derivative present in Garlic.
Gamma-glutamyl S-allyl cysteine is a Cysteine derivative present in Garlic.
Eventually the gas is converted to sulfite in the mitochondria by thiosulfate reductase, and the sulfite is further oxidized to thiosulfate and sulfate by sulfite oxidase. The sulfates are excreted in the urine.
Due to its effects similar to nitric oxide (without its potential to form peroxides by interacting with superoxide), hydrogen sulfide is now recognized as potentially protecting against cardiovascular disease. The cardioprotective role effect of garlic is caused by catabolism of the polysulfide group in allicin to H2S, a reaction that could depend on reduction mediated by glutathione.
Though both nitric oxide (NO) and hydrogen sulfide have been shown to relax blood vessels, their mechanisms of action are different: while NO activates the enzyme guanylyl cyclase, H2S activates ATP-sensitive potassium channels in smooth muscle cells. Researchers are not clear how the vessel-relaxing responsibilities are shared between nitric oxide and hydrogen sulfide. However there exists some evidence to suggest that nitric oxide does most of the vessel-relaxing work in large vessels and hydrogen sulfide is responsible for similar action in smaller blood vessels.
Recent findings suggest strong cellular crosstalk of NO and H2S, demonstrating that the vasodilatatory effects of these two gases are mutually dependent. Additionally, H2S reacts with intracellular S-nitrosothiols to form the smallest S-nitrosothiol (HSNO), and a role of hydrogen sulfide in controlling the intracellular S-nitrosothiol pool has been suggested.
Like nitric oxide, hydrogen sulfide is involved in the relaxation of smooth muscle that causes erection of the penis, presenting possible new therapy opportunities for erectile dysfunction.
In Alzheimer's disease the brain's hydrogen sulfide concentration is severely decreased. In trisomy 21 (Down syndrome) the body produces an excess of hydrogen sulfide. Hydrogen sulfide is also involved in the disease process of type 1 diabetes. The beta cells of the pancreas in type 1 diabetes produce an excess of the gas, leading to the death of beta cells and to a reduced production of insulin by those that remain.
Garlic has long been touted as a health booster, but it’s never been clear why the herb might be good for you. Now new research is beginning to unlock the secrets of the odoriferous bulb.
In a study published today in the Proceedings of the National Academy of Sciences, researchers show that eating garlic appears to boost our natural supply of hydrogen sulfide. Hydrogen sulfide is actually poisonous at high concentrations — it’s the same noxious byproduct of oil refining that smells like rotten eggs. But the body makes its own supply of the stuff, which acts as an antioxidant and transmits cellular signals that relax blood vessels and increase blood flow.---In the latest study, performed at the University of Alabama at Birmingham, researchers extracted juice from supermarket garlic and added small amounts to human red blood cells. The cells immediately began emitting hydrogen sulfide, the scientists found. The power to boost hydrogen sulfide production may help explain why a garlic-rich diet appears to protect against various cancers, including breast, prostate and colon cancer, say the study authors. Higher hydrogen sulfide might also protect the heart, according to other experts. Researchers at Albert Einstein College of Medicine earlier this year found that injecting hydrogen sulfide into mice almost completely prevented the damage to heart muscle caused by a heart attack.
[U1]I love this term “missed” or would it mean over looked because they knew the issues in the day and now are beginning to further there agenda
[U2]Is someone else bell ringing on this??/they have the most sophistcaed equipment on the planet and they “ MISSED THIS!”---who are we kidding here
[U5]Not Safe for Human consumption???---I have been saying this for over 10 years about the fact we are consuming viruses and now here it is and as a result we maybe consuming direct via vege fruit or
[U6]Now this is an irony we proclaim the dangers of this virus and now we do not know enough til future experiments---sounds like a money grab to me to further to agenda 21
[U7]What a lousy example to use –canada is worse---since there is no official labeling or unofficial –there is no bases for this statement---if there was labeling and people ate the food knowing what was in it would determine the cause of the illness or debilitation---since we do not record this then there is really no double blind just a stating of hypothesis
[U8]Question I ask how many people did they settle out of court or pay off just so this would not be reported—thereby altering the statistics?
[U9]Doesn’t this sound like a FDA buy out?? Is this not what happened to the USA and any other FDA affiliations globally!! When you read this and it is showing 54/86 GMO crops are contaminated and they are feeding this to the livestock and it can damage both animal and humans---what then is this saying???!!! It is saying here there will be a negotiation with the EFSA to hide research like this as well as other things being hidden so people cannot make accurate decisions and keep on following options that are presented rather then choices
[U10]Things to look forward to---and they want to disarm people here in North America when this kind of insanity is going on globally—if this were to happen here in North America) CAN/USA) then we will have a problem—a lot of people do not have any skills other then what they have programmed to do---others have lost there capacity to be autonomous---these people will panic and proceed to burglarize and kill to have what the perceive---stay armed and prepared and stocked
[U11]Guns instead of grains---what stupidty---or is it planned?
[U12]Could it be a weather modification attack—could it be a HAARP or RF attack?? Could the drought be a way to insure cooperation?? Makes me go hmm
[U14]This is why if you must go through this insanity then take essiac teas---dandelion and turmeric teas to offset the side effect of the chemo ---not to mention protecting your liver as a result of the detoxing these poison that you will excrete
Show of the Month February 23 2013
Men Taking Long-Acting Chronic Pain Meds Five Times More Likely to Have Low Testosterone Levels
Egg For Burns
Working Alone Won't Get You Good Grades
Effectiveness of castor oil extract on Escherichia coli and its endotoxins in root canals
Let’s look at the thyroid and see what we can do to assist in sustaining a healthy thyroid—
Thyroxine is the primary Hormone synthesized and secreted by the Thyroid Gland - Thyroxine comprises 80% of the Thyroid Hormone secretions. Thyroxine is less potent than Triiodothyronine (T3).--Thyroxine is the second most prescribed Pharmaceutical Drug (based on the number of prescriptions dispensed in the USA during 1999[U1] ).---What does the thyroid really need to be optimal---would be things derived from foods unless there has been some kind genetic interference with what would normally regenerate the system—
T4--Some of the body’s Thyroxine content is converted to Triiodothyronine (T3).- Tyrosine is an essential cofactor (along with Iodine) for the production of Thyroxine within the body - Tyrosine comprises 35% of Thyroxine-- Sunlight may stimulate the production of Thyroxine-Iodine is a cofactor for the production of Thyroxine from Tyrosine-Copper is involved in the conversion of Triiodothyronine to Thyroxine- Approximately 20% of the body's supply of Iodine is used as an essential cofactor (with Tyrosine) in the production of Thyroxine within the body - Iodine comprises 65% of Thyroxine--Selenium is required for the conversion of Thyroxine (T4) into Triiodothyronine (T3)- Selenium is essential for the production of the enzyme that converts Thyroxine (T4) into Triiodothyronine (T3) -Vitamin C may facilitate the production of Thyroxine.
T3- Triiodothyronine is a type of minor Hormone produced in and secreted by the Thyroid Gland - Triiodothyronine accounts for 20% of Thyroid Hormone production. Triiodothyronine is approximately ten times more potent than Thyroxine (T4).--Although often under-discussed, the majority (80% - 85%) of biologically-active Triiodothyronine is produced in peripheral tissues other than the Thyroid Gland - specifically the Liver and (to a lesser extent) the Kidneys. This occurs via the conversion of Thyroxine (T4) to Triiodothyronine.-- Tyrosine is an essential cofactor (in conjunction with Iodine) for the production of Triiodothyronine--- Copper may enhance the conversion of Triiodothyronine to Thyroxine.---5% of the body's Iodine is used in the production of Triiodothyronine (Iodine comprises 59% of the chemical structure of Iodine).--- Phosphorus may help to prevent decreases in plasma Triiodothyronine levels.--Selenium is an essential cofactor for the production of Triiodothyronine:
Things that can interfere with T3 or T4
Soybeans may inhibit the production of Triiodothyronine (due to the Isoflavonoids content of Soybeans). Seeds-Fenugreek Seeds may lower the body’s levels of Triiodothyronine by inhibiting the conversion of Thyroxine to Triiodothyronine- Fluoride may inhibit the production and action of Thyroxine- Isothiocyanates- Excessive consumption of some types of Isothiocyanates[U2] may cause Goiter or Hypothyroidism by blocking the utilization of Iodine and consequently slowing down the function of the Thyroid.-These Iodine blocking Isothiocyanates were formerly known as Goitrogenic Substances-- Legumes:Soybeans-Nuts:Peanuts-Vegetables: Cabbages—Cauliflower-Brussels Sprouts-Broccoli-Kale--- Brussels Sprouts Chinese Broccoli-Choy Sum-Daikon-Kale-Kohlrabi-Mustard Greens-Radish-Rutabaga-Turnip---the same component that can shut down the thyroid as well can be of use in the body ---but with a compromised thyroid these should be consumed sparingly til the thyroid is mended and even then to make sure that adequate iodine is use with selenium and copper
Things to use to maintain or rebuild thyroid
Iodine-1-4 drops a day and increase 1 drop til at desired dose
Tyrosine -500-1,500mgs a day-fermented dairy
Selenium-100mcg’s 3-4 times a day-brazil nuts are the highest sources
Copper- 1-3 mgs a day—green leafy veges --Chlorophyll
Phosphorus -1000mgs –Nuts and Seeds—Sunflower Lecithin-Eggs
Vitamin C- 1-5 grams a day—Supplement Ascorbic acid in some form
Men Taking Long-Acting Chronic Pain Meds Five Times More Likely to Have Low Testosterone Levels
Jan. 31, 2013 — Low testosterone levels occur five times more often among men who take long-acting instead of short-acting opioids for chronic pain, according to a new Kaiser Permanente study published in The Clinical Journal of Pain.--While it has been known that opioids cause low testosterone in men, this study is the first to show a significant difference in risk between short-acting (immediate release) and long-acting opioids.---The 81 men in the retrospective study were between 26 and 79 years old (median age 51) and were seen in the chronic-pain clinic at Kaiser Permanente's Santa Rosa Medical Center (Calif.) between January 2009 and June 2010. All of the participants had been on a stable dose of an opioid for at least three months, and none had a previous diagnosis of low testosterone. A larger retrospective study of more than 1,500 male pain patients is currently under way.----"There's a large gap in the evidence base with regard to opioids," said Andrea Rubinstein, MD, of the Departments of Chronic Pain and Anesthesiology, Kaiser Permanente Santa Rosa Medical Center. "More safety and efficacy studies are needed. We need to know how we can prescribe these very useful medications in a way that brings the greatest benefits to our patients, without introducing additional risks."---Once prescribed primarily to cancer patients, the use of opioid-based medications such as oxycodone (Oxycontin) and hydrocodone (Vicodin) for treating chronic, non-cancer pain has increased dramatically in recent decades. An estimated 4.3 million Americans use opioids on a daily basis for pain.---"For years, doctors have been encouraged to prescribe long-acting opioids rather than short-acting opioids because we believed they were safer, had less abuse potential, and offered more consistent pain control, but no study has ever been able to support this practice," Dr. Rubinstein said.--The study compared the use of short-acting opioids, which immediately release the pain medication and are taken every four to six hours, and long-acting opioids, which slowly release the pain medication and are taken every eight to 12 hours.A healthy young man should have testosterone levels between 300 and 800 nanograms per deciliter (ng/dL); in this study, low testosterone, also known as hypogonadism, was defined as less than 250 ng/dL. Low testosterone levels have been associated with decreases in muscle mass, bone density (osteoporosis or osteopenia), cognition, mood, libido (sex drive) and general quality of life.---Seventy-four percent of the men on long-acting opioids had low testosterone levels, compared with 34 percent of the men using short-acting opioids. After controlling for daily dosage and body mass index, the study found that the odds of having low testosterone were 4.78 times greater for men taking a long-acting opioid than a short-acting opioid. Dose was not associated with an increased risk of low testosterone.---"These medications work well for short-term, acute pain," said Dr. Rubinstein. "It has long been extrapolated that they can also be used safely long-term to control chronic pain. We are now finding that the long-term use of opioids may have important unintended health consequences."
Co-authors of the study were Diane M. Carpenter, MPH, Kaiser Permanente Division of Research; and Jerome R. Minkoff, MD, Kaiser Permanente Department of Endocrinology, Santa Rosa Medical Center.--Story Source--The above story is reprinted from materials provided by Kaiser Permanente, via EurekAlert!, a service of AAAS. ---Journal Reference--Andrea L. Rubinstein, Diane M. Carpenter, Jerome R. Minkoff. Hypogonadism in Men With Chronic Pain Linked to the Use of Long-acting Rather Than Short-acting Opioids. The Clinical Journal of Pain, 2013; DOI: 10.1097/AJP.0b013e31827c7b5d
Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
Therapeutic Uses for Compositions Containing Stabilized Crosslinked Lipase Crystals
Also included in the invention are methods for treating or preventing gastrointestinal disorders in a mammal. According to this method, a therapeutically effective to amount of a crosslinked crystalline lipase, protease, amylase composition is administered to a subject in need of treatment. The subject to can be e.g., a human, dog, cat, mouse, rat, horse, cow, or other mammal. Preferably, the composition is administered orally, e.g., at mealtime. For example, the composition can be administered just before, just after, or while eating.
The compositions of the invention can be used to treat or prevent, for example, pancreatitis, pancreatic insufficiency, fat malabsorption, low lipase secretion, and gastrointestinal complications associated with cystic fibrosis. The methods of this invention can be also be used to treat any condition characterized by inadequate amounts of or ineffective lipase. Such conditions include steatorrhea, essential fatty acid deficiency, failure to thrive, and fat-soluble vitamin deficiency.
The effectiveness of the method of treatment can be assessed by measuring and comparing the coefficient of fat absorption (CFA) in healthy individuals with that of the subject being treated according to the methods of this invention. For example, a healthy mammal has a CFA greater than 90%. Subjects suffering from a gastrointestinal disorder characterized by pancreatic deficiency, pancreatitis, fat malabsorption or low lipase secretion, will typically have a CFA of less than 60%. Preferably, the methods of this invention are employed to increase the CFA of a subject in need of treatment to at least 60%. More preferably, the CFA is increased to greater than 80%. Most preferably, the CFA is increased to greater than 85%.
An alternative means for measuring the efficacy of treatment of a subject according to the methods of this invention is by performing a 72 hour stool test. For example, effective treatment according to the invention decreases stool fat content in an adult human subject to less than 7 grams a day
Egg For Burns
young man sprinkling his lawn and bushes with pesticides wanted to check the contents of the barrel to see how much pesticide remained in it. He raised the cover and lit his lighter; the vapors ignited and engulfed him. He jumped from his truck, screaming.. His neighbor came out of her house with a dozen eggs and a bowl yelling: "bring me some more eggs!" She broke them, separating the whites from the yolks.
The neighbor woman helped her to apply the whites onto the young man's face.
When the ambulance arrived and the EMTs saw the young man, they asked who had done this. Everyone pointed to the lady in charge. They congratulated her and said: "You have saved his face." By the end of the summer, the young man brought the lady a bouquet of roses to thank her. His face was like a baby's skin. Keep in mind this treatment of burns is being included in teaching beginner fireman.
First Aid consists of first spraying cold water on the affected area until the heat is reduced which stops the continued burning of all layers of the skin. Then, spread the egg whites onto the affected area. One woman burned a large part of her hand with boiling water. In spite of the pain, she ran cold faucet water on her hand, separated 2 egg whites from the yolks, beat them slightly and dipped her hand in the solution. The whites then dried and formed a protective layer. She later learned that the egg white is a natural collagen and continued during at least one hour to apply layer upon layer of beaten egg white. By afternoon she no longer felt any pain and the next day there was hardly a trace of the burn. 10 days later, no trace was left at all and her skin had regained its normal color. The burned area was totally regenerated thanks to the collagen in the egg whites, a placenta full of vitamins.
Working Alone Won't Get You Good Grades
A graph showing interactions between 82 students during the last week of a course. High performing students are in dark blue and form a core where the highest density of persistent interactions can be observed. Mid-performing students are in red and low-performing student sin green. Persistent interactions are shown in thick blue edges, while dotted thin grey edges indicate transient interactions.---Jan. 31, 2013 — Students who work together and interact online are more likely to be successful in their college classes, according to a study published Jan. 30 in the journal Nature Scientific Reports and co-authored by Manuel Cebrian, a computer scientist at the Jacobs School of Engineering at the University of California San Diego.---Cebrian and colleagues analyzed 80,000 interactions between 290 students in a collaborative learning environment for college courses. The major finding was that a higher number of online interactions was usually an indicator of a higher score in the class. High achievers also were more likely to form strong connections with other students and to exchange information in more complex ways. High achievers tended to form cliques, shutting out low-performing students from their interactions. Students who found themselves shut out were not only more likely to have lower grades; they were also more likely to drop out of the class entirely.---"Elite groups of highly connected individuals formed in the first days of the course," said Cebrian, who also is a Senior Researcher at National ICT Australia Ltd, Australia's Information and Communications Technology Research Centre of Excellence. "For the first time, we showed that there is a very strong correspondence between social interaction and exchange of information -- a 72 percent correlation," he said "but almost equally interesting is the fact that these high-performing students form 'rich-clubs', which shield themselves from low-performing students, despite the significant efforts by these lower-ranking students to join them. The weaker students try hard to engage with the elite group intensively, but can't. This ends up having a marked correlation with their dropout rates."----This study co-authored by Luis M. Vaquero, based at Hewlett-Packard UK Labs, shows a way that we might better identify patterns in the classroom that can trigger early dropout alarms, allowing more time for educators to help the student and, ideally, reduce those rates through appropriate social network interventions.---Cebrian's work is part of UC San Diego's wider research effort at the intersection of the computer and social sciences, led by Prof. James H. Fowler, to enhance our understanding of the ways in which people share information and how this impacts areas of national significance, such as the spread of health-related or political behavior.--Story Source-The above story is reprinted from materials provided by University of California - San Diego. --Journal Reference-Luis M. Vaquero, Manuel Cebrian. The rich club phenomenon in the classroom. Scientific Reports, 2013; 3 DOI: 10.1038/srep01174
Effectiveness of castor oil extract on Escherichia coli and its endotoxins in root canals.
Gen Dent. 2012 Jul-Aug;60(4):e204-9
Authors: Valera MC, Maekawa LE, Chung A, de Oliveira LD, Carvalho CA, Koga-Ito CY, Jorge AO
This in vitro study sought to evaluate the effectiveness of castor oil extract used as an irrigating solution on Escherichia coli and its endotoxins in root canals. Sixty single-rooted teeth were prepared (using castor oil extract as irrigating solution) and divided into five groups (n = 12): Group 1 samples were treated with calcium hydroxide (Ca(OH)2), Group 2 samples were treated with polymyxin B, Group 3 samples were treated with Ca(OH)2 and 2% chlorhexidine gel (CHX), and Group 4 samples were treated with castor oil extract. A control group used physiological saline solution as an irrigant. Canal content samples were collected at four different times: immediately after instrumentation, seven days after instrumentation, after 14 days of intracanal medication, and seven days after removal of intracanal medication. A plating method was used to assess antimicrobial activity and the quantification of endotoxins was evaluated by the chromogenic Limulus lysate assay. Data were submitted to ANOVA and a Dunn test (a = 5%). Irrigation with castor oil extract decreased E. coli counts but had no effect on the level of endotoxins. Samples taken seven days after removal of medication revealed a significant reduction in endotoxin levels in Groups 3 and 4. Compared to the saline solution irrigation, castor oil extract decreased microorganism counts in root canals immediately after canal preparation. None of the medications used completely eliminated endotoxins in the root canal.--PMID: 22782052 [PubMed - indexed for MEDLINE]
[U1]This means that a drug such as this may reduce the effective capacity for the thyroid to work and regulate itself---when giving out a drug to replace what occurs naturally ---you shut down the organ or gland and this can further perpetrate other health issues